university of veterinary medicine hannover › servlets › ... · university of veterinary...
TRANSCRIPT
University of Veterinary Medicine Hannover
Institute for Food Toxicology and Analytical Chemistry
The effect of resveratrol and resveratrol imine analogues on human
tumor cell lines
THESIS
Submitted in partial fulfilment of the requirements for the degree
DOCTOR OF PHILOSOPHY
(PhD)
awarded by the University of Veterinary Medicine Hannover
by
Shan Wang
Henan, P.R. China
Hannover, Germany 2016
Supervisor: Prof. Dr. Pablo Steinberg
Supervision Group: Prof. Dr. Pablo Steinberg
Prof. Dr. Hassan Y. Naim
Prof. Dr. Peter Winterhalter
1st Evaluation: Prof. Dr. Pablo Steinberg
Institute for Food Toxicology and Analytical Chemistry,
University of Veterinary Medicine Hannover, Germany
Prof. Dr. Hassan Y. Naim
Department of Physiological Chemistry,
University of Veterinary Medicine Hannover, Germany
Prof. Dr. Peter Winterhalter
Department of Food Chemistry,
Technical University of Braunschweig, Germany
2nd Evaluation: Prof. Dr. Sabine Kulling
Department of Safety and Quality of Fruit and Vegetables,
Max Rubner-Institut, Karlsruhe, Germany
Date of final exam: 06.04.2016
Shan Wang received financial support from the China Scholarship Council (CSC).
To my family
Publications and presentations:
Publications:
Empl, M. T., Albers, M., Wang, S., Steinberg, P. (2015): The resveratrol tetramer r-viniferin
induces a cell cycle arrest followed by apoptosis in the prostate cancer cell line LNCaP.
Phytother Res 29(10):1640-1645.
Oral Presentations:
Wang, S., Empl, M. T., Steinberg, P.: Antiproliferative effect of an imine analogue of resveratrol
on human tumor cells. 23rd
VETPHARM-Symposium. Sep. 12.-13. 2013, Giessen, Germany.
Poster presentation:
Wang, S., Empl, M. T., Steinberg, P.: The antiproliferative effect of imine analogues of resveratrol
on human tumour cells. 11th International PhD Student Symposium, Horizons in Molecular Biology.
September 09.-12. 2013, Göttingen, Germany.
Wang, S., Empl, M. T., Steinberg, P.: Inhibitory effects of resveratrol imine analogues on the
proliferation and cell cycle progression of human tumor cells. Annual Spring Congress of the
European Society of Veterinary Oncology, May 28.-30. 2015, Krakow, Poland.
Contents
Abbreviations ................................................................................................................................................ I
Summary ...................................................................................................................................................... III
Zusammenfassung ...................................................................................................................................... V
1. Introduction ........................................................................................................................................... 1
1.1. Cancer and dietary polyphenols ................................................................................................... 1
1.2. Effect of resveratrol in vitro and in vivo studies ....................................................................... 2
1.3. Resveratrol analogues ..................................................................................................................... 6
1.4. The cell cycle and its regulation .................................................................................................... 7
1.5. The COX-2/PGE2 pathway................................................................................................................ 9
1.6. The aim of study .............................................................................................................................. 14
2. Materials and Methods ...................................................................................................................... 15
2.1. Materials............................................................................................................................................. 15
2.2. Methods ............................................................................................................................................. 16
3. Results ................................................................................................................................................. 23
3.1. Growth inhibitory effect of the test substances ...................................................................... 23
3.2. Cell cycle distribution analysis .................................................................................................... 34
3.3. Effect of resveratrol and compound 5 on the COX-2/PGE2-pathway ................................. 46
3.4. Metabolic stability of compound 5 .............................................................................................. 48
4. Discussion .......................................................................................................................................... 49
4.1. Effect of resveratrol and IRAs on the proliferation of human tumor cell lines ............... 49
4.2. Effect of resveratrol and compound 5 on cell cycle distribution ........................................ 50
4.3. Effect of resveratrol and compound 5 on the COX-2/PGE2-pathway ................................. 54
4.4. Metabolism of compound 5 .......................................................................................................... 54
5. References .......................................................................................................................................... 57
6. Annex ................................................................................................................................................... 73
7. Acknowledgments ............................................................................................................................. 77
Abbreviation
I
Abbreviations
AA Arachidonic acid
ANOVA Analysis of variance
Apc Adenomatous polyposis coli
APS Ammonium persulfate
BSA Bovine serum albumin
CDK Cyclin-dependent kinase
COX Cyclooxygenase
dH2O Distilled water
DMEM Dulbecco's Modified Eagle Medium
DMSO Dimethyl sulfoxide
DMSZ German Collection of Microorganisms and Cell Culture
DNA Deoxyribonucleic acid
DTT Dithiothreitol
ECL Electrochemiluminescence
EDTA Ethylenediaminetetraacetic acid
EtOH Ethanol
FasL Fas ligand
FBS Fetal Bovine Serum
HEPES-buffer 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid buffer
HRP Horseradish peroxidase
IC50 Half maximal inhibitory concentration
IgG Immunoglobulin G
LC-MS Liquid chromatography-mass spectrometry
LC-UV Liquid chromatography-ultraviolet detection
M Molar
mA Milliampere
mM Milimolar
NF-kB Nuclear factor kB
NSAIDs Non-steroidal anti-inflammatory drugs
P/S Penicilin/Streptomycin
PBS Phosphate-buffered saline
Abbreviation
II
PGG Prostaglandin G
PGH Prostaglandin H
PGE2 Prostaglandin E2
PGs Prostaglandins
PI Propidium iodide
PMSF Phenylmethylsulfonyl fluoride
RCF Relative centrifugal force
RNA Ribonucleic acid
RNAse A Ribonuclease A
RPMI-1640 Medium Roswell Park Memorial Institute Medium
SD Standard deviation
SDS Sodium dodecyl sulfate
SRB Sulforhodamine B
T/E Trypsin/EDTA
TEMED Tetramethylethylenediamine
TRIS Tris-(hydroxymethyl)-aminomethane
V Volt
μm Micrometer
Summary
III
Summary
The effect of resveratrol and resveratrol imine analogues on human tumor cell
lines
Shan Wang
Dietary polyphenols such as resveratrol, which are commonly present in fruits and
vegetables, have been shown to possess cancer chemopreventive effects in vitro.
Resveratrol has been described as a cancer chemopreventive agent due to its growth
inhibiting activity in several different tumor cell lines. However, its chemopreventive
effect in vivo is a matter of debate, predominantly because of its low bioavailability.
Therefore, resveratrol analogues with potentially stronger health-promoting effects
have attracted the interest of the scientific community. Newly synthesized resveratrol
imine analogues (IRAs) have been reported as inducing stronger antioxidative effects
than resveratrol itself, but information regarding their potential anticarcinogenic
activities is still very limited. Therefore, the biological properties of five IRAs on
different human tumor cell lines were investigated.
The antiproliferative activity of five IRAs was first evaluated in HCT-116p53wt cells. The
results show that only compound 5 exerted a stronger antiproliferative effect than
resveratrol, whereas the other compounds were either not or only slightly cytotoxic.
Thus, only compound 5 was chosen as a candidate for studies to determine its ability
to inhibit the growth of various cancer cell lines, to modulate COX-2 protein
expression and to analyze its metabolic stability.
In agreement with previous studies, resveratrol led to a growth inhibition in cancer cell
lines, however, the effect was cell type-dependent. In this respect, compound 5
showed a similar behavior. Flow cytometric analyses revealed that both compounds
induce alterations in the cell cycle, thus indicating that the growth inhibitory effect of
resveratrol and compound 5 is associated with a cell cycle dysregulation. Western blot
Summary
IV
analyses confirmed the down-regulation of COX-2 protein expression after resveratrol
treatment in the HCA-7 cell line. In contrast, compound 5 induced the expression of
that protein. Further analyses by LC-MS revealed that resveratrol as well as
compound 5 both inhibited PGE2 production. Finally, the metabolic stability of
compound 5 was investigated by an in vitro glucuronidation assay, which revealed
that this IRA is less conjugated than resveratrol by rat liver microsomes.
In conclusion, the effects of compound 5 on human tumor cells is similar to that of
resveratrol, but the bioavailability of compound 5 is higher, mainly owing to the fact
that it is conjugated to a lesser extent than resveratrol itself.
Zusammenfassung
V
Zusammenfassung
Die Wirkung von Resveratrol und Resveratrol-Imin-Analoga auf humane
Tumorzelllinien
Shan Wang
In der Ernährung vorkommende Polyhenole wie Resveratrol, welche allgemein in
Früchten und Gemüse vorhanden sind, weisen in vitro antikanzerogene
Eigenschaften. Resveratol wurde als krebshemmende Substanz beschrieben, da sie
das Wachstum einer Reihe von Tumorzelllinien hemmt. Trotzdem ist seine
krebspräventive Wirkung in vivo sehr beschränkt, vorwiegend auf Grund seiner
geringen Bioverfügbarkeit. Deshalb hat die Suche nach Resveratrol-Analoga mit einer
potenziell stärkeren gesundheitsfördernden Wirkung als Resveratrol das
wissenschaftliche Interesse geweckt. In jüngster Zeit synthetisierte
Resveratrol-Imin-Analoga (IRAs) sollen eine stärkere antioxidative Wirkung im
Vergleich zu Resveratrol aufweisen; ihre antikanzerogene Aktivität ist bis heute aber
kaum untersucht worden. Aus diesemGrund wurden die biologischen Wirkungen von
fünf IRAs in verschiedenen Humantumorzelllinien untersucht.
In einem ersten Schritt wurde die antiproliferative Wirkung von fünf IRAs in
HCT-116p53wt-Zellen getestet. Die Ergebnisse zeigen, dass nur die Substanz 5 eine
stärkere Wirkung als Resveratrol aufwies, während die anderen Substanzen gar
keine oder nur eine geringfügige Zytotoxizität zeigten. Somit wurde nur die Substanz
5 bezüglich einer hemmenden Wirkung auf das Wachstum von Tumorzelllinien, der
Regulation der Expression von COX-2 und dessen metabolischen Stabilität weiter
untersucht.
In Übereinstimmung mit vorangegangenen Untersuchungen führte Resveratrol zu
einer Hemmung des Wachstums verschiedener Humantumorzelllinien, die jedoch
vom Zelltyp abhängig war. Diesbezüglich zeigte auch die Substanz 5 ein ähnliches
Verhalten. Durchflusszytometrische Untersuchungen bestätigten, dass beide
Zusammenfassung
VI
Substanzen zu Veränderungen im Zellzyklus führten, was darauf hinweist, dass die
hemmende Wirkung von Resveratrol und Substanz 5 in Verbindung mit der
Dysregulation des Zellzyklus steht. Eine Western-Blot-Analyse bestätigte die
Herunterregulation der COX-2-Proteinexpression nach Behandlung mit Resveratrol in
HCA-7 Zellen. Im Gegensatz dazu, induzierte die Substanz 5 die Expression dieses
Proteins. Weiterhin zeigt eine LC-MS-Analyse, dass sowohl Resveratrol als auch die
Substanz 5 die PGE2-Produktion unterdrücken können. Letztendlich wurde mittels
eines Glucuronidierungs-Assays die metabolische Stabilität der Substanz 5 in vitro
untersucht. Dabei wurde nachgewiesen, dass dieses IRA in einem geringeren
Umfang als Resveratrol durch Rattenleber-Mikrosome glucuronidiert wird.
Zusammenfassend lässt sich sagen, dass die Wirkung der Substanz 5 und
Resveratrol auf menschliche Tumorzelllinien ähnlich ist, dass aber die
Bioverfügbarkeit der Substanz 5 höher ist, da sie in geringerem Maße konjugiert wird.
Introduction
1
1. Introduction
1.1. Cancer and dietary polyphenols
Cancer is still a main health problem and one of the major reasons for mortality
worldwide (ZENG et al. 2013). There are over 100 different types of cancer, including
lung, prostate, colon, stomach, and breast cancer. An estimate of cancer incidence,
mortality and prevalence by the World Health Organization (WHO) showed that in
2012 there were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6
million people who are living with cancer (FERLAY et al. 2015; FITZMAURICE et al.
2015).
The causes of cancer are complex. 90-95 % of cancer cases can be attributed to
environmental factors, whereas the remaining 5-10 % is due to genetic factors
(ANAND et al. 2008). Environmental factors include diet, smoking, obesity, alcohol,
low amounts of physical exercise, as well as stress, radiation and environmental
pollutants. Although the inherited factors are not modifiable, some environmental
factors such as diet, tobacco consumption and physical inactivity can be controlled
(DIVISI et al. 2006). Therefore, cancer can be considered, at least partially, a
preventable disease, and much of the cancer burden could be lowered by a lifestyle
change.
In this context, a “good” dietary consumption and regular physical exercise may be
important modifiable ways for reducing cancer incidence (BOFFETTA et al. 2010;
DAVIES et al. 2011; YUSOF et al. 2012). A healthy diet on the one hand means
consuming food mostly based on plants (such as fruits, vegetables and products
gained from them), while on the other hand ingesting less red meat and salt (DAVIES
et al. 2011). It has been shown that fruits and vegetables present in the diet have
potentially preventable effects on cancer (DIVISI et al. 2006). Various substances in
these food products have been identified (STEINMETZ et al. 1996; MANACH et al.
2004). For example, flavones in fruits, quercetin in plant products and resveratrol in
Introduction
2
plants were intensely studied due to their potential beneficial health effects in humans
(D'ARCHIVIO et al. 2010).
Some studies have indicated that dietary polyphenols commonly found in vegetables
and fruits may play a role in the prevention of diseases such as cancer and
cardiovascular disorders (SCALBERT et al. 2000; SCALBERT et al. 2005).
Resveratrol is one of most studied compounds because of its cardioprotective,
antiinflammatory and antioxidative effects in animals and human cell lines (POULSEN
et al. 2013; RAEDERSTORFF et al. 2013; GAMBINI et al. 2015). However, preventive
effects in animals and human cell lines are difficult to extrapolate to humans, and
results from a few clinical studies proved not to be reproducible (ARTS et al. 2001;
ARTS et al. 2002; SCALBERT et al. 2005).
1.2. Effect of resveratrol in vitro and in vivo studies
1.2.1. Background on resveratrol
Resveratrol (3,5,4’-trihydroxystilbene, Figure 1.1) is a polyphenol found in many
plants and plant products such as grapes, peanuts and red wine (BHAT et al. 2001b).
Its content is 50-100 mg per gram grape skin and 0.2 mg/l to 7.7 mg/l in red wine
(CELOTTI et al. 1996). After the discovery of the so-called “French Paradox”, the
potential health-promoting properties of resveratrol have attracted a lot of attention.
The “French Paradox” describes the phenomenon that French people take up high
amounts of saturated fat but show a low incidence of coronary heart diseases (CHD)
when compared to other countries, and this has been partly attributed to the high wine
consumption in France (FERRIERES 2004). In addition to its antiinflammatory,
antioxidative and cardioprotective properties, resveratrol also could suppress cancer
progression.
JANG et al. (1997) found out that resveratrol induces a cancer-preventive effect,
which is associated with the three major steps of carcinogenesis. In that study,
resveratrol induced quinone reductase (phase II enzyme) activity, which is associated
Introduction
3
with the inhibition of tumor initiation, inhibited the cyclooxygenase and
hydroperoxidase activities, which correlates with tumor promotion, and inhibited
preneoplastic lesions in 7,12-dimethylbenz[a]anthracene (DMBA)-treated mouse
mammary glands. This finding attracted much scientific interest regarding the
anticarcinogenic activity of resveratrol.
Figure 1.1: The structure of trans-resveratrol (JANG et al. 1997)
1.2.2. In vitro studies
Resveratrol has been shown to inhibit the proliferation of various tumor cell lines, for
example cells originating from colon, prostate, breast, head and neck, liver, lung,
stomach, pancreatic and muscle cancers (HSIEH et al. 1999; ATTEN et al. 2001;
MAHYAR-ROEMER et al. 2001; MATSUOKA et al. 2001; SERRERO et al. 2001; JOE
et al. 2002; KUWAJERWALA et al. 2002; POZO-GUISADO et al. 2002; NARAYANAN
et al. 2003; POUSSIER et al. 2005; BUJANDA et al. 2006; KIM et al. 2006; LIN et al.
2008; CUI et al. 2010; ZHOU et al. 2011; LIU et al. 2012; FOUAD et al. 2013).
Exposure to 25 μM resveratrol caused a 70 % growth inhibition in Caco-2 cells, which
was due to the accumulation of cells at the S/G2 phase transition of the cell cycle
(SCHNEIDER et al. 2000). Moreover, the growth of androgen-responsive and
androgen-nonresponsive cancer cells was inhibited by this substance (HSIEH et al.
1999; KUWAJERWALA et al. 2002). In another colon cancer cell line, resveratrol
inhibited proliferation, which was associated with a decrease of the cyclin D1/CDK4
protein complex and an increase of cyclin E and cyclin A levels (WOLTER et al. 2001).
In addition to the suppression of cellular proliferation, resveratrol can induce apoptosis
Introduction
4
via different pathways. It has been shown to induce apoptosis through the activation
of the mitochondrial apoptosis pathway in a p53-independent manner in HCT-116
cells (MAHYAR-ROEMER et al. 2001). DELMAS et al. (2003) reported that
resveratrol-induced apoptosis in SW-480 cells was associated with the activation of
Bax and Bak proteins. Resveratrol also induced apoptosis in HL-60 and T47D cells,
which was specifically dependent on Fas signaling (CLEMENT et al. 1998). This
pathway also seems to be the predominantly activated one in HCT-116 cells; in this
context. MAHYAR-ROEMER et al. (2001) described that resveratrol induced
apoptosis through the intrinsic apoptotic pathway (by accumulation of p21 and BAX).
Resveratrol-induced apoptosis is associated with the activation of p53 (SHE et al.
2002). p53 is a tumor suppressor gene and plays an important role in apoptosis.
Normally, it is inactive (through binding to Mdm2), and (in most cases) only activated
in response to oncogenic stress/DNA damage (through the ATM/ATR pathway) in
order to induce cell cycle arrest and apoptosis (MAXIMOV et al. 2008).
The inhibitory activity of resveratrol on cyclooxygenase-2 (COX-2) has been
suggested to be a major factor contributing to its anti-cancer activity (JANG et al.
1997). Research studies indicated that the incubation of HCA-7 cells with resveratrol
for 24-96 h suppressed COX-2 protein expression and prostaglandin E2 (PGE2)
production. COX-2 expression was shown to be controlled by NF-kappaB, and COX-2
expression also inhibits the nuclear translocation of NF-kB, thereby suggesting a dual
role for COX-2 (POLIGONE et al. 2001). Additional studies support the view that
resveratrol suppresses DMBA-induced mammary carcinogenesis, which is associated
with the suppression of DMBA-induced NF-kappaB activation and COX-2 expression
(BANERJEE et al. 2002).
1.2.3. In vivo studies
Besides its effects in vitro, resveratrol also has been investigated regarding its activity
in vivo. LI et al. (2002) demonstrated that resveratrol could decrease the size and
number of tumors in DMBA-treated rats. Moreover, it was shown that resveratrol was
Introduction
5
able to reduce the formation of preneoplastic ductal lesions and inhibit mammary
tumorigenesis (BHAT et al. 2001a). In another study, it was suggested that resveratrol
inhibits PMA-promoted mouse skin tumors and that tumorigenesis in mouse skin was
associated with reactive oxygen species-related pathways (JANG et al. 1998).
TESSITORE et al. (2000) investigated the effect of resveratrol on azoxymethane
(AOM)-induced colon carcinogenesis in male F344 rats for 100 days, and the results
showed that resveratrol decreased the formation of colonic aberrant crypt foci by 40 %
and their multiplicity by 50 %.
The number of clinical studies performed with resveratrol in humans is still small.
Resveratrol was shown to be absorbed from grape juice and to reduce the risk of
atherosclerosis (PACEASCIAK et al. 1996). The absorption of resveratrol in humans
is high, but its bioavailability is low (WALLE et al. 2004). A pharmacokinetics
investigation in healthy adult subjects showed that the mean peak concentration of
resveratrol in plasma was low after oral administration, thus suggesting that high-dose
resveratrol consumption in humans cannot induce the same chemopreventive effect
as in vitro (BOOCOCK et al. 2007a). Moreover, after the oral consumption of
resveratrol, it was mainly present as glucuronide and sulfate conjugates in serum and
urine (GOLDBERG et al. 2003).
Due to the structure of resveratrol, it is easily metabolized to sulfates and
glucuronides in the intestine and liver (TOME-CARNEIRO et al. 2013). Extensive
metabolism of resveratrol is an important factor responsible for its low bioavailability.
KUHNLE et al. (2000) showed in an isolated rat small intestine model that only small
amounts of resveratrol remained unmetabolized and only small amounts of
resveratrol were absorbed across the enterocytes of the jejunum and ileum. However,
the low amount of bioavailable resveratrol might still exert a cancer-preventive effect
due to its accumulation in certain tissues and to the resveratrol metabolites (WALLE et
al. 2004; WALLE 2011). For example, the potential biological properties of
dihydroresveratrol (a metabolite of resveratrol) might be important to enhance the
Introduction
6
activity of resveratrol (KAGEURA et al. 2001; STIVALA et al. 2001;
ROTCHES-RIBALTA et al. 2012).
1.3. Resveratrol analogues
Since bioavailability limits the activity of resveratrol, research has focused on the
search or synthesis of new resveratrol analogues, with the aim of finding optimized
and more potent substances regarding growth-inhibition activity and metabolic
stability (SALE et al. 2005). Metabolites of resveratrol hydroxylated at the aromatic
rings demonstrated a higher COX-2 inhibition rate than celecoxib (a selective COX-2
inhibitor) (MURIAS et al. 2004). The anti-tumor activity of resveratrol triacetate was
also reported to inhibit cell growth and lead to a cell cycle arrest in human
adenocarcinoma colon cells (MAREL et al. 2008). r-Viniferin (a resveratrol tetramer)
was found to inhibit the growth of LNCaP cells and to induce a cell cycle arrest in the
G1 phase, which was accompanied by a higher apoptotic activity than resveratrol
(EMPL et al. 2015). The synthetic resveratrol analog 3,4,5,4'-tetramethoxystilbene
(DMU-212) was reported to exert a stronger anti-proliferative activity than resveratrol
in human colon cancer cells (SALE et al. 2004).
Imine resveratrol analogues (IRAs, Figure 1.2) are a series of synthetic polyphenols,
in which the C=C double bond has been replaced by a C=N bond in addition to
several modifications at the aromatic rings (LU et al. 2012). IRAs are easy to
synthesize and have a higher antioxidative activity than resveratrol. SERSEN et al.
(2009) found out that these analogues have the potential to scavenge DPPH radicals.
The replacement of the C=C double bond in the resveratrol molecule does not lead to
a loss of its antioxidant effects (LU et al. 2012; KOTORA et al. 2016). In addition, IRAs
also were shown to exert neuroprotective effects (LI et al. 2014). The synthesized
resveratrol analogues possess an antiinflammatory potential by significantly reducing
the activity of NF-kB (GOBEC et al. 2015). The anticarcinogenic effect of the
synthesized analogues was shown to be stronger than that of resveratrol. In this
context, it has been shown that they can inhibit human breast cancer cell growth by
Introduction
7
inhibiting the activation of protooncogenes by an estrogen receptor-dependent
pathway (RONGHE et al. 2014). However, studies regarding the biological effects of
IRAs are still scarce.
Figure 1.2: The structure of IRAs (LU et al. 2012)
1.4. The cell cycle and its regulation
The cell cycle is a cyclic procedure leading from the end of one cell division to the end
of the next cell division and in which a series of events end up in DNA replication
(VERMEULEN et al. 2003). The correct cell division is essential for the development
of tissues, and cell cycle control is important for an appropriate repair when a DNA
damage has occurred during this process (LODISH et al. 2008).
The cell cycle is divided in four different phases (Figure 3). Before entering the G1
phase, cells can remain in a resting stage (G0 phase), which is a phase of
non-proliferation. Cell division starts when the cells enter the G1 phase. In this phase,
cells prepare DNA synthesis and chromosome replication, i.e. prepare for the S phase.
Introduction
8
DNA replication occurs during the S phase, resulting in a doubled DNA content. In the
G2 phase, cells prepare for cell division. The subsequent process of mitosis, also
called the M (mitotic) phase, is the phase in which the nucleus and cytoplasm are
divided to yield two daughter cells. These can then re-enter the cell cycle or enter the
resting phase (This paragraph is summarized from LODISH et al. (2008)).
In each phase, there are a number of different cellular proteins that regulate the
transition between the G1, S, G2 and M phases. They consist of the cyclin subunit and
the cyclin-dependent kinase (CDK) subunit. Cyclins were first discovered in 1982
(EVANS et al. 1983; PINES 1991). They are synthesized during the cell cycle and
degraded in the M phase. CDKs can be activated by cyclins and form a cyclin-CDK
complex, which is important to ensure an accurate cell division (LEES 1995;
ARELLANO et al. 1997).
The cyclin-CDK complexes in each phase are different (VERMEULEN et al. 2003).
CDK 2 is important when cells enter the S and G2 phase. For example, the cyclin
E/A-CDK 2 complex can help the cells enter the S phase from the G1 phase, and the
cyclin A-CDK 2 complex is active between the S and G2 phases. Moreover, the cyclin
D-CDK 4/6 complex assists the cell through the G1 phase and the cyclin A/B-CDK 1
complex helps in the progression of the cells into the M phase (GALDERISI et al.
2003; SATYANARAYANA et al. 2009). For the correct cell division and progression of
the cell cycle, a strict control is essential. Checkpoints assure the proper order of cell
cycle events, regulate the progress of the cell cycle, and arrest the cell cycle in case
there is (DNA) damage that needs time to be repaired (HARTWELL et al. 1989;
ELLEDGE 1996).
Introduction
9
Figure 1.3: Overview of the cell cycle (LODISH et al. 2008)
Unrestrained cell proliferation could cause cancer (VERMEULEN et al. 2003). The
mutation of some genes may lead to cell cycle dysregulation, which in turn may lead
to tumor formation (CHAMPERIS TSANIRAS et al. 2014). EASTON et al. (1998)
described an alteration of CDK4 and CDK6 genes, which leads to the loss of
p16INK4a gene binding in neuroblastoma cells. p53 is a tumor suppressor gene; its
reduced expression is related to an increased risk of tumor formation
(VENKATACHALAM et al. 1998). A G1 phase arrest can be induced by p53; It acts by
enhancing the expression of the cyclin-dependent kinase inhibitor 1 (p21CIP), which in
turn inhibits CDKs 2, 4 and 6 (Figure 3) (SHAW 1996).
1.5. The COX-2/PGE2 pathway
Cyclooxygenase (COX) is an enzyme which is involved in prostaglandin synthesis
(VANE et al. 1998). There are two forms of COX. COX-1 was first cloned from sheep
in 1988 (DEWITT et al. 1988; YOKOYAMA et al. 1988), and is known to maintain the
normal lining of the gastrointestinal system and present in most tissues (KARGMAN
Introduction
10
et al. 1996; JACKSON et al. 2000). In contrast to that, COX-2 is mainly expressed in
sites of inflammation and undetectable in many normal tissues (ONOE et al. 1996;
SEIBERT et al. 1997; JACKSON et al. 2000). COX-2 is mainly expressed in response
to growth factors, cytokines or tumor promoters (DEWITT et al. 1993; EBERHART et
al. 1994; ONOE et al. 1996; RISTIMAKI et al. 1997).
The antitumor activity and mechanisms action of non-steroidal anti-inflammatory
drugs (NSAIDs) have been analyzed in a number of in vitro and in vivo studies
(KELLER et al. 2003). The mode of action of most NSAIDs is based on the inhibition
of COX, which in turn leads to a reduced production of prostaglandins (VANE 1971;
ABRAMSON et al. 1989). Both COX-2 and its main product PGE2, play a key role in
the development of cancer. COX-2 expression is upregulated in human colonic
tumors, and PGE2 has been demonstrated to promote tumor cell proliferation
(KANAOKA et al. 2007; NAKANISHI et al. 2013). DI POPOLO et al. (2000) showed
that the use of aspirin or other NSAIDs lowers the risk of colorectal cancer, and these
findings support the view that the COX-2/PGE2 pathway plays an important role in
cancer development (KELLER et al. 2003).
1.5.1. COX-2
COX-2 is an enzyme whose biosynthesis can be induced by diverse growth factors as
well as cytokines, and it is known that COX-2-expression is closely associated with
inflammatory mediators and signs of inflammation (BAKHLE et al. 1996; RUMZHUM
et al. 2015). Because of the fact that NSAIDs also block COX-1, which is constitutively
expressed in normal gastrointestinal tissue, intake of high NSAID doses may cause
gastrointestinal and ulcerative diseases (TRAVERSA et al. 1995; MALFERTHEINER
et al. 2009). Selective COX-2 inhibitors (“coxibs”) have the advantage, when
compared to regular NSAIDs, that they only target COX-2, but clinical data have
shown that COX-2 inhibitors can lead to a high incidence of cardiovascular diseases
(FUNK et al. 2007).
The link between chronic inflammation and cancer has been confirmed in a number of
Introduction
11
studies, and inflammation might play a role in tumor development, including tumor
initiation, promotion and proliferation (SUGANUMA et al. 1999; COUSSENS et al.
2002; HUSSAIN et al. 2007). COX-2, which is normally induced in inflammation,
appears to be directly implicated in tumor development. Overexpression of COX-2
has also been demonstrated in colorectal and breast cancer cells (CAO et al. 2002;
SECCHIERO et al. 2005). It has been suggested that COX-2 could increase mutated
cell growth and affect cell death (CHAN et al. 2007; SOBOLEWSKI et al. 2010).
COX-2 overexpression is related to the production of PGE2, which is known to inhibit
cell growth and tumor invasion.
Studies have shown that NSAIDs and selective COX-2 inhibitors may reduce the risk
of cancer. Celecoxib significantly reduced tumor size (to about 17 %) and multiplicity
(to about 29 %) in C57BL/6J (Min/+) male mice (the adenomatous Apc mutant Min
mouse model), and its adenoma preventing effect is thought to be based on the
inhibition of the conversion of arachidonic acid to prostaglandins (JACOBY et al.
2000). Similarly, celecoxib has shown tumor preventive effects regarding breast
cancer development in in vitro and in vivo experiments (DAI et al. 2012), and induced
apoptosis in human prostate cancer cells (HSU et al. 2000).
COX-2 is a tumor therapy target for many compounds. Polyphenols could reduce
tumor progression through inhibition of COX-2. Quercetin metabolites can
down-regulate COX-2 expression in human colon cells, which may be the basis of its
chemopreventive effect (MIENE et al. 2011). The anti-tumor activity of resveratrol can
be attributed in part to the inhibition of COX-2 protein expression (SALE et al. 2005).
Green tea polyphenols have been shown to exert an inhibitory effect on COX-2 in
colon carcinogenesis (PENG et al. 2006).
1.5.2. PGE2
Prostaglandin E2 (PGE2) was discovered by Bunting in 1976 (BUNTING et al. 1976). It
is a member of the prostanoid family, is synthesized from arachidonic acid (AA) and
plays a predominant role in inflammation as well as cancer development and
Introduction
12
promotion (PARK et al. 2006; NAKANISHI et al. 2013). PGE2 has diversity important
regulatory functions, including the regulation of body temperature, inflammation,
glucose metabolism, cell growth and other physiological activities (MURAKAMI et al.
2004). It is known that PGE2 protects the gut mucosa and inhibits gastric acid
secretion (BRZOZOWSKI et al. 2005; DEY et al. 2006).
PGE2 has also been described as a cancer promoting agent. The mechanism of
action is based on the binding of PGE2 to its cognate receptors (EP1-4), which results
in an increase of cell proliferation, apoptosis inhibition, cell invasion, and immune
response suppression (WANG et al. 2006). The main role of PGE2 in tumor
progression has been attributed to the activated EP receptor, subsequently triggering
different signaling pathways. PGE2 promoted the motility and invasiveness of human
colorectal carcinoma cells (SHENG et al. 2001). Administration of PGE2 to male F344
rats could increase the incidence and multiplicity of colon adenomas (KAWAMORI et
al. 2003). In vitro and in vivo data support the tumor-promoting effect of PGE2.
However, PGE2 also has tumor inhibiting effects. WILSON et al. (2000) reported that
treatment of Min/+ mice with a stable PGE2 analogue (16,16-dimethyl-PGE2) for 8
weeks clearly decreased the number and size of tumors (10-70%) in the whole
intestine, which suggests that PGE2 perhaps has the ability to inhibit tumor
development in some cases.
Introduction
13
Figure 1.4: The COX-2/PGE2 pathway (SOBOLEWSKI et al. 2010). The COX-2
enzyme is responsible for catalyzing arachidonic acid to prostaglandin G2 (PGG2),
and subsequently to prostaglandin H2 (PGH2). Then, PGH2 is converted to different
prostaglandins, which mediate their effects through different receptors
(SOBOLEWSKI et al. 2010).
Introduction
14
1.6. The aim of study
Since the bioavailability of resveratrol is limited in vivo by its fast metabolism, and the
chemopreventive activity of newly generated resveratrol analogues has not been
elucidated, we investigated the biological properties of five IRAs on human tumor cell
lines and compared them with those of resveratrol.
The aims of study were the following:
1. To examine the anti-proliferative activity of IRAs on human colorectal carcinoma as
well as other tumor cell lines and compare it to that of resveratrol.
2. To investigate the effects of resveratrol and the most potent IRA(s) on the cell
cycle distribution of the above-mentioned cell lines.
3. To investigate the effects resveratrol and the most potent IRA(s) on COX-2
expression and activity
4. To investigate the metabolic stability of the most potent IRA(s)
Materials and methods
15
2. Materials and Methods
2.1. Materials
2.1.1. Chemicals
Dimethyl sulfoxide (DMSO), ethanol, trichloroacetic acid (TCA), acetic acid,
phenylmethylsulfonyl fluoride (PMSF), urea, sodium dodecyl sulfate (SDS),
tris-(hydroxymethyl)-aminomethane (Tris), glycine, ammonium persulfate (APS),
nocodazole, powdered milk, methanol, NaCl, glucose, isopropanol, and
acrylamide-bisacrylamide solution (37.5:1) were purchased from Carl Roth (Karlsruhe,
Germany), while ribonuclease A (RNase A), sulforhodamine B (SRB), propidium
iodide (PI) solution, protease inhibitor cocktail, dithiothreitol (DTT), Ponceau S,
tetramethylethylenediamine (TEMED), goat anti-rabbit IgG-HRP, and resveratrol were
acquired from Sigma-Aldrich (Taufkirchen, Germany). Cell culture reagents such as
fetal bovine serum (FBS), sodium bicarbonate (NaHCO3) solution,
4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) buffer, non-essential
amino acids (NEA) solution, trypsin/EDTA (T/E), trypan blue solution and all cell
culture media were purchased from Biochrom (Berlin, Germany). The resveratrol
imine analogues (IRAs, purity ≥ 99 %) were kindly provided by the research group of
Prof. Dr. Y. Pan (Zhejiang University, Hangzhou, P.R. of China). In terms of an easy
identification, we named them compound 1, 2, 3, 4 and 5 (Figure 1.2). The exact
composition of all buffers used in the present study can be found in the annex.
2.1.2. Other materials
Ionic detergent compatibility reagent (IDCR) Thermo Scientific
Pierce 660nm protein assay reagent Thermo Scientific
GAPDH antibody Santa Cruz
Biotinylated protein ladder Santa Cruz
COX-2 antibody Cell Signaling
Materials and methods
16
Goat anti-mouse IgG-HRP Cell Signaling
peqGOLD protein-marker IV PEQLAB Biotechnologie
Bromophenol blue sodium salt AppliChem
Tween® 20 Prolabo
ECL solution (HRP-substrate) Millipore
2.1.3. Cell lines
HCT-116p53wt Colorectal carcinoma DMSZ
HCT-116p53-/- Colorectal carcinoma Provided by Prof. Dr. Regina
Schneider-Stock (Institute of
Pathology,University of Erlangen,
Erlangen, Germany)
A-431 Epidermoid carcinoma ATCC
Caco-2 Adenocarcinoma DMSZ
LNCaP Prostate carcinoma DMSZ
HCA-7 Adenocarcinoma ECACC
2.2. Methods
2.2.1. Cell culture
HCT-116p53wt cells were grown in RPMI 1640 medium supplemented with 10 % (v/v)
FBS, 2 mM L-glutamine and 100 IU/mL penicillin/100 μg/mL streptomycin. A-431,
HCA-7 and HCT-116p53-/- cells were grown in Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10 % (v/v) FBS, 2 mM L-glutamine and 100 IU/mL
penicillin/100 μg/mL streptomycin. LNCaP cells were grown in RPMI 1640 medium
supplemented with 10% (v/v) FBS, 2 mM L-glutamine, 100 IU/mL penicillin/100 μg/mL
streptomycin, 0.15 % NaHCO3, 1 mM sodium pyruvate, 10 mM HEPES, and 4.5 g/L
glucose. Caco-2 cells were grown in DMEM supplemented with 10% (v/v) FBS, 2 mM
L-glutamine, 100 IU/mL penicillin/100 μg/mL streptomycin and 1% (v/v) NEA.
Materials and methods
17
All cell lines were incubated at 37 °C in an atmosphere with 5 % CO2 and 95 %
relative humidity. To count the cells, a hemocytometer and the trypan blue exclusion
method were used (STROBER 2001). Resveratrol and the five resveratrol imine
analogues were dissolved in DMSO, aliquoted in 0.5 ml centrifuge tubes and stored at
-20 °C until use.
2.2.2. Cell proliferation measurements
The proliferation of cells was determined by the SRB assay (SKEHAN et al. 1990) as
previously described (VICHAI et al. 2006), but with slight alterations. Briefly, 1000 (in
the case of the cell lines HCT-116, A-431, Caco-2, HCA-7) or 3000 cells (in the case
of the cell line LNCaP) per well were seeded into 96-well plates (TPP®, Trasadingen,
Switzerland). Then, the cells were treated with the solvent control (0.1 % DMSO) and
increasing concentrations of resveratrol as well as the resveratrol imine analogues (1,
5, 10, 20, 40, 60, 80, 100 µM) and incubated for 48, 72 or 120 h. Thereafter, cellular
proteins were fixed by the addition of 50 % TCA solution. Subsequently, 70 μl of a
0.4 % (w/v) SRB solution were added to each well, and the plates rinsed five times
with 1 % acetic acid after an incubation time of 55 min. Finally, 100 μl of a 10 mM Tris
buffer were added to each well and the absorption measured at 510 nm in a plate
reader (infinite® M200; Tecan, Crailsheim, Germany).
Materials and methods
18
2.2.3. Flow cytometry
Cell cycle analyses were performed with slight changes as previously described
(EMPL et al. 2015). In short, 1.5 x 106 cells were seeded in 10 cm cell culture dishes
(TPP) and incubated for 24 hours. Culture medium was then replaced by 10 ml fresh
FBS-free medium for another 24 h. Then, the cells were exposed to 0.1 % DMSO
(solvent control), the test substances (resveratrol and compound 5; 10, 40, 80 μM) or
10 μM nocodazole (positive control) for 24 and 48 h. In a next step, the supernatants
were collected in 50 ml tubes and the cells detached by the addition of a T/E solution.
Both the supernatant and the cells were then combined in the same tube.
Subsequently, the cells were centrifuged and 1 x 106 cells (in 300 µl cold PBS)
transferred drop by drop to a new 1.5 ml centrifuge tube containing 700 μl of ethanol.
Samples were then stored at 4 °C until analysis. After staining with PI, the DNA
content was measured using BD Accuri® C6 cytometer (BD Biosciences, Heidelberg,
Germany) controlled by the CFlow Plus software (version 1.0.264.15; BD Biosciences,
Heidelberg, Germany). 20,000 events were gated and the flow rate was set to
14 μL/min for each sample. Finally, the acquired data was analyzed with FlowJo
(version 7.6.5; FlowJo, Ashland, OR, USA).
2.2.4. Protein extraction and Western blotting
2.2.4.1. Sample preparation
1.6 x 106 cells/10 ml medium were seeded in 10-cm cell culture dishes and left to
attach for 24 h. Then, the cells were exposed to fresh medium containing the control
(0.1 % DMSO) and the test substances (resveratrol and compound 5 [1, 50, 100 μM])
for 24 h. In order to collect the cellular protein, the cell culture dishes were placed on
ice, the adherent cells were scrapped off the dishes with a plastic spatula (TPP), and
the supernatant transferred to 50 ml tubes. Remainders in the dishes were washed
down twice with 5 ml cold PBS and transferred to the same 50 ml tubes. The mixtures
were then centrifuged at 4 °C and 12,000 rcf for 15 min. Thereafter, the supernatant
Materials and methods
19
was aspirated, while the cell pellet was resuspended in 1 mL cold PBS and
transferred to a new 1.5 mL centrifuge tube. Then, the tubes were centrifuged at 4 °C
and 4,400 rcf for 10 minutes and the samples stored at -80 °C overnight.
Subsequently, the samples were lysed with the cell lysis buffer (100-200 μL) by
incubating each sample on ice for 60 min accompanied by vortexing intervals every
10 min as well as a 10 s sonication step. Finally, the samples were stored at -80 °C
until protein quantitation.
2.2.4.2. Determination of protein concentration
The protein concentration of all samples was measured by using the Pierce 660 nm
protein assay kit according to the manufacturer’s instructions.
2.2.4.3. Western blotting
For electrophoresis (SDS-PAGE), a 10 % gel was prepared. 20 μg protein of each
sample were transferred to a 1.5 ml centrifuge tube together with 5 x and 2 x loading
buffer to reach a final sample volume of 30 μl/lane. Additionally, 8 μl of protein marker
and 10 μl of biotinylated protein ladder were added to 1.5 ml centrifuge tubes. The
tubes were then shaken and shortly centrifuged, and the proteins were denaturized by
boiling at 95 °C for 5 min. In a next step, 20 μg of total protein were loaded onto each
well of the gel, along with the protein markers/ladders. The separation was firstly
performed for 30 min at 30 mA, before the current was increased to 50 mA for about
1 h until the proteins were separated. The transfer onto nitrocellulose blotting
membranes (GE Healthcare Life Science, UK) was done under “wet” conditions.
Firstly, the gel was taken off the glass and placed in cold transfer buffer for 10 min.
The membrane and filter paper were soaked in cold transfer buffer before being used.
Then, the gel and membrane were tightly “sandwiched” between two sponges and
three filter papers and the proteins transferred onto the membrane at 30 V for 12-16 h
using a Mini trans-blot® cell system (Bio-Rad Laboratories GmbH, München,
Germany). After the transfer, the membrane was stained with Ponceau S solution to
Materials and methods
20
check the transfer quality and to enable cutting into two pieces, which was accurately
performed at 50 kDa. Then, both membrane pieces were rinsed three times with
washing buffer until the Ponceau S solution was completely removed. Subsequently,
the membrane was blocked in 5 % milk blocking buffer at room temperature for 2 h
under shaking. Thereafter, the primary antibody (Table 2.1) was diluted in blocking
buffer and bathed with the membrane overnight at 4 °C, before being washed with
washing buffer 3 times for 5 min. The HRP-conjugated secondary antibody was
prepared with blocking buffer and contained an HRP-linked anti-biotin antibody (Table
2.2). Then, an incubation with the HRP-conjugated secondary antibody for 1 h at
room temperature was performed, the membrane rinsed three times for 5 min with
washing buffer and ECL substrate applied as recommended by the manufacturer.
Images of the blots were finally obtained by using an Imager (INTAS, Göttingen,
Germany).
Table 2.1 Primary Antibody
Protein binding Species Company Dilution Clone
COX-2 Rabbit Cell Signaling 1:1000 Polyclonal
GAPDH Mouse Santa Cruz 1:2000 Polyclonal
Materials and methods
21
Table 2.2 Secondary Antibody
Protein binding Species Company Dilution Clone
Rabbit-IgG Goat Sigma-Aldrich 1:1000 Polyclonal
Mouse-IgG Goat Santa Cruz 1:10,000 Polyclonal
Biotin Goat Cell Signaling 1:1000 Polyclonal
2.2.5. LC−UV and LC-MS Analysis
LC−UV and LC-MS analyses were performed by Michael Krohn and Ina Willenberg as
previously described (WILLENBERG et al. 2012; WILLENBERG et al. 2015b)
2.2.6. Glucuronidation Assays
The glucuronidation assay was carried out by Michael Krohn as described
(WILLENBERG et al. 2012)
2.2.7. Statistical analysis
For data analysis and IC50-value calculation, GraphPad Prism version 6 (GraphPad
Software Inc., San Diego, CA, USA) was used. A p value ≤ 0.05 was considered to be
statistically significant.
Materials and methods
22
Results
23
3. Results
3.1. Growth inhibitory effect of the test substances
3.1.1. Effect of resveratrol and IRAs on colon cancer cell proliferation
The growth inhibitory activity of resveratrol and five IRAs was first investigated in the
human colorectal carcinoma cell line (HCT-116p53wt). Cells were exposed to the test
substances at concentrations of 1-100 μM for 48, 72 and 120 h. As shown in Figure
3.1, the properties of the compounds differ.
While resveratrol and compound 5 showed a strong inhibition of cellular growth, the
other compounds had no such pronounced effects on HCT-116p53wt cells. The
inhibitory activity of resveratrol is thereby dependent on time and dose. The cell
growth inhibition by resveratrol started at a concentration of 20 μM after 48 h and
reached a value of 92 % after 120 h of treatment with 100 μM (Fig. 3.1 F). The effect
of compound 5 is also time as well as dose-dependent and much stronger than
resveratrol, as the earliest significant growth inhibition effects were already seen at a
concentration of 1 μM after 72 h of incubation. Maximum growth inhibition (95 %) was
observed at a concentration of 100 μM after 120 h of treatment (Fig. 3.1 E).
In general, the other four compounds showed no marked cytotoxic activity towards the
above-mentioned colon cancer cell line. The cells still survived when exposed to
compound 1 and compound 3 (Fig. 3.1 A and C), while compound 2 and compound 4
had a slight inhibitory effect on cell growth (22 and 19 % at concentrations of 60 μM
and 80 μM after 120 h of incubation, respectively) (Fig. 3.1 B and D).
Results
24
Figure 3.1: Inhibitory effect of resveratrol (F) and IRAs (A-E) on the proliferation of HCT-116p53wt cells. Results are presented as
mean ± standand deviation (SD) of five independent experiments. ▪: p ≤ 0.05; #: p ≤ 0.01; +: p ≤ 0.001; *: p ≤ 0.0001
Results
25
3.1.2. Effect of resveratrol and compound 5 on the proliferation of other tumor
cell lines
After determining the most potent IRA in the previous step, we analysed the
growth-inhibiting effects of resveratrol and compound 5 on other cancer cell lines (the
p53-deficient colorectal carcinoma cell line HCT-116p53-/-, the epidermoid carcinoma
cell line A-431, the prostate carcinoma cell line LNCaP, the colorectal
adenocarcinoma cell line Caco-2, and the colonic adenocarcinoma cell line HCA-7).
Generally, compound 5 and resveratrol also induced a strong growth-inhibiting effect
in the above-mentioned cell lines. This effect was cell line-dependent. In HCT-116p53-/-
cells, after 48 h of treatment, 20 μM resveratrol was able to significantly suppress cell
growth (Fig. 3.2 A). After 120 h, the cell count decreased to about 13 % of the control
value when the cells were treated with the highest concentration (100 μM). Compound
5 also inhibited cellular proliferation, a marked inhibition starting at 10 μM after 72 h of
incubation and a 90 % maximal inhibition reached when the cells were exposed to a
concentration of 100 μM after 120 h (Fig. 3.2 B).
Results
26
Figure 3.2: Inhibitory effect of resveratrol (A) and compound 5 (B) on the proliferation
of HCT-116p53-/- cells. Results are presented as mean ± SD of five independent
experiments. #: p ≤ 0.01; *: p ≤ 0.0001
Results
27
In the A-431 cells, both resveratrol and compound 5 were able to inhibit the cell
growth in a time- and dose-dependent manner (Fig. 3.3 A and B). After 72 h of
incubation, resveratrol and compound 5 reduced cell number significantly, starting at 5
and 10 μM, respectively. The maximum inhibition rates were approximately 90 % for
both test compounds (100 μM resveratrol and compound 5).
Figure 3.3: Inhibitory effect of resveratrol (A) and compound 5 (B) on the proliferation
of A-431 cells. Results are presented as mean ± SD of five independent experiments.
#: p ≤ 0.01; +: p ≤ 0.001; *: p ≤ 0.0001
Results
28
As in A-431 cells, the growth-inhibiting activity of compound 5 is similar to that of
resveratrol in LNCaP cells, both substances starting to reduce cell proliferation at a
low concentration (5 μM) after 72 h of treatment. 100 μM resveratrol and compound 5
caused a 69 % growth inhibition (Figure 3.4 A and B).
Figure 3.4: Inhibitory effect of resveratrol (A) and compound 5 (B) on the proliferation
of LNCaP cells. Results are presented as mean ± SD of five independent experiments.
#: p ≤ 0.01; +: p ≤ 0.001; *: p ≤ 0.0001
Results
29
The same can be also said for Caco-2 cells: A treatment of the cells with 10 µM of
both compounds already led to a significant suppression of cell growth. After treating
the cells with 100 µM resveratrol and compound 5 for 120 h, the percentage of the
remaining cells was 12 % and 15 % of the control value, respectively (Figure 3.5 A
and B).
Figure 3.5: Inhibitory effect of resveratrol (A) and compound 5 (B) on the proliferation
of Caco-2 cells. Results are presented as mean ± SD of five independent experiments.
#: p ≤ 0.01; +: p ≤ 0.001; *: p ≤ 0.0001
Results
30
While resveratrol and compound 5 also led to a time- and dose-dependent growth
inhibition in HCA-7 cells, this cell line was more resistant to the cytotoxic effects
emanating from the test compounds. This assumption is supported by the fact that the
growth inhibition reached values of 72 and 68 % when the cells were treated with
100 μM resveratrol and compound 5. Interestingly, resveratrol was more cytotoxic
than compound 5, as shown by the fact that first significant effects were observed with
10 μM resveratrol and 20 μM compound 5 (Figure 3.6 A and B).
Figure 3.6: Inhibitory effect of resveratrol (A) and compound 5 (B) on the proliferation
of HCA-7 cells. Results are presented as mean ± SD of six independent experiments.
▪: p ≤ 0.05; #: p ≤ 0.01; +: p ≤ 0.001; *: p ≤ 0.0001
Results
31
3.1.3. IC50 calculation
The IC50 values of resveratrol and IRAs in the six above-mentioned tumour cell lines
were computed as described in chapter 2.2.7. In HCT-116p53wt cells, the
growth-inhibitory potency of compound 5 is approximately 50 times higher than that of
resveratrol, with an IC 50 value of 0.59 vs 31.01 μM (Table 3.1). The other four IRAs
showed no noteworthy cytotoxic effect on the growth of HCT-116p53wt cells. In all the
other tumour cell lines tested, resveratrol and compound 5 were able to inhibit cell
growth, but the effect was cell line-dependent. In HCT-116p53-/- cells, the IC50 value of
compound 5 was 2 times lower than that of resveratrol, contrasting the effects in
A-431 cells (Table 3.2). In LNCaP and Caco-2 cells, the IC50 value of both compounds
was quite similar. Moreover, in HCA-7 cells, the inhibitory effect of compound 5 was
2-4 times higher than that in the other tumour cell lines.
Table 3.1: IC50 values of resveratrol and IRAs in HCT-116p53wt cells after 120 h
IC50 (μM)
C 1 C 2 C 3 C 4 C 5 resveratrol
HCT-116p53wt 151.1 303 - 1507 0.59 31.01
The values (μM) represent the mean of five independent experiments. -: IC50 cannot be
calculated.
Results
32
Table 3.2: IC50 values of resveratrol and compound 5 in HCT-116 p53-/-, A-431, LNCaP,
Caco-2 and HCA-7 cells
IC50 (μM)
HCT-116p53-/- A-431 LNCaP Caco-2 HCA-7
R 28.61 9.19 29.55 16.09 33.78
C 5 16.09 15.42 24.88 13.38 51.60
The values (μM) represent the mean of six independent experiments.
Results
33
Results
34
3.2. Cell cycle distribution analysis
The previous chapter showed that resveratrol and compound 5 exerted cell
growth-inhibitory effects on different tumor cell lines, which might be due to alterations
of the cell cycle. Therefore, the effects of resveratrol and compound 5 on the cell cycle
distribution of the above-mentioned cell lines were investigated.
3.2.1. Effect of resveratrol and compound 5 on the cell cycle distribution of
HCT-116p53wt cells
At 10 μM, compound 5 led to a slight decline of the percentage of cells in the S phase,
which was associated with an increased (p≤0.05) population of cells in the G2 phase
(Figure 3.7 A). However, after 48 h no such an effect was observed (Figure 3.7 B).
When cells were grown in the presence of 40 μM compound 5 a significant increase
(p≤0.0001) in the percentage of cells being in the S phase after 24 h was observed
(Figure 3.7 C). After 48 h of incubation, compound 5 seemed to enhance the number
of cells in the G1 phase, but not significantly (Figure 3.7 D). At the highest used
concentration (80 μM), compound 5 caused a significant S phase accumulation only
after 24 h of treatment (Figure 3.7 E). In contrast, resveratrol induced an accumulation
in the S phase at 40 μM after 24 h, strongly associated with a decrease of cells in the
G1 and G2 phase (Figure 3.7 C). At 80 μM (Figure 3.7 E and F), resveratrol led to an
accumulation of cells in the G1 phase after 24 h and in the S phase after 48 h.
Results
35
Figure 3.7: Effect of resveratrol and compound 5 (10 μM 24 h: A; 10 µM 48 h: B;
40 μM 24 h: C; 40 µM 48 h: D; 80 μM 24 h: E; 80 µM 48 h: F) on the cell cycle
distribution of HCT-116p53wt cells. Results are presented as mean ± SD of four
independent experiments. ▪: p ≤ 0.05; *: p ≤ 0.0001.
Results
36
3.2.2. Effect of resveratrol and compound 5 on the cell cycle distribution of
HCT-116p53-/- cells
As can be seen in Figure 3.8 A and B, 10 μM resveratrol led to an accumulation of
cells in the S phase after 24 h (P≤0.01) and 48 h (P≤0.05) of incubation. In contrast,
compound 5 did not cause any alteration of the cell cycle after 24 h of incubation. At
40 μM, a higher percentage of resveratrol-treated cells were arrested in the S phase
after 24 h of treatment, while compound 5 led to a significant arrest after both 24 and
48 h of incubation (Figure 3.8 C and D). At the highest concentration (80 μM) and after
24 h, resveratrol and compound 5 led to an increase of cells in the G1 and S phase
(p≤0.01), respectively, whereas after 48 h resveratrol and compound 5 led to an
accumulation of cells in the S and G2 phase, respectively (Figure 3.8 E and F).
Results
37
Figure 3.8: Effect of resveratrol and compound 5 (10 μM 24 h: A; 10 µM 48 h: B;
40 μM 24 h: C; 40 µM 48 h: D; 80 μM 24 h: E; 80 µM 48 h: F) on the cell cycle
distribution of HCT-116p53-/- cells. Results are presented as mean ± SD of four
independent experiments. ▪: p ≤ 0.05; #: p ≤ 0.01; +: p ≤ 0.001; *: p ≤ 0.0001.
Results
38
3.2.3. Effect of resveratrol and compound 5 on the cell cycle distribution of
A-431 cells
As early as after 24 h, a treatment of the cells with 10 μM resveratrol induced a
significant increase of cells in the G1 phase (Figure 3.9 A), while a concentration of
40 μM resveratrol led to an S phase arrest (Figure 3.9 C). However, both compounds
failed to cause any effect at 10 and 40 μM after 48 h of incubation (Figure 3.9 B and
D). When the cells were treated with an 80 μM concentration of the two test
compounds, a high proportion of cells were arrested in the S phase, this effect being
accompanied by a decrease of cells in the G1 phase (Figure 3.9 E and F).
Results
39
Figure 3.9: Effect of resveratrol and compound 5 (10 μM 24 h: A; 10 µM 48 h: B;
40 μM 24 h: C; 40 µM 48 h: D; 80 μM 24 h: E; 80 µM 48 h: F) on the cell cycle
distribution of A-431 cells. Results are presented as mean ± SD of four independent
experiments. ▪: p ≤ 0.05; #: p ≤ 0.01; +: p ≤ 0.001; *: p ≤ 0.0001.
Results
40
3.2.4. Effect of resveratrol and compound 5 on the cell cycle distribution of
LNCaP cells
As early as after 24 h, a treatment with 10 μM resveratrol induced a significant
increase of cells in the G1 phase (Figure 3.9 A) and to an S phase arrest after a
treatment with 40 μM (Figure 3.9 C). However, both compounds failed to cause any
effect at 10 and 40 μM after 48 h of incubation (Figure 3.9 B and D). When the cells
were treated with an 80 μM concentration of the two test compounds, a high
proportion of cells were arrested in the S phase, an effect that was accompanied by a
decrease of cells in the G1 phase (Figure 3.9 E and F).
Results
41
Figure 3.10: Effect of resveratrol and compound 5 (10 μM 24 h: A; 10 µM 48 h: B;
40 μM 24 h: C; 40 µM 48 h: D; 80 μM 24 h: E; 80 µM 48 h: F) on the cell cycle
distribution of LNCaP cells. Results are presented as mean ± SD of four independent
experiments. #: p ≤ 0.01; *: p ≤ 0.0001.
Results
42
3.2.5. Effect of resveratrol and compound 5 on the cell cycle distribution of
Caco-2 cells
At a rather low concentration of 10 μM, resveratrol and compound 5 failed to lead to
any effect on the cell cycle distribution in Caco-2 cell line (Figure 3.11 A and B). At
40 μM, both test compounds led to a significant arrest of these cells in the S phase
(P≤0.0001; Figure 3.11 C and D). At 80 μM, only compound 5 induced an alteration of
the cell cycle distribution in a time-dependent manner (Figure 3.11 E and F). In
contrast, resveratrol-treated cells were not affected regarding the G1, S or G2 phase
distribution of the cells; instead, an increase of cells in the Sub-G1 fraction was
observed.
Results
43
Figure 3.11: Effect of resveratrol and compound 5 (10 μM 24 h: A; 10 µM 48 h: B;
40 μM 24 h: C; 40 µM 48 h: D; 80 μM 24 h: E; 80 µM 48 h: F) on the cell cycle
distribution of Caco-2 cells. Results are presented as mean ± SD of four independent
experiments. +: p ≤ 0.001; *: p ≤ 0.0001
Results
44
3.2.6. Effect of resveratrol and compound 5 on the cell cycle distribution of
HCA-7 cells
Subsequently, the effect of resveratrol and compound 5 in HCA-7 cells was
investigated. As seen in Figure 3.12 A, C and E, compound 5 led to an accumulation
of cells in the G1 phase, which was accompanied by a decrease of the cellular faction
in the S and G2 phase after 24 h. After 48 h, cells were mainly detected in the S phase
when treated with 80 μM compound 5. Resveratrol had no effect on the cell cycle
distribution at a low concentration (Figure 3.12 A and B), and cells were mainly
arrested in the G1 phase at a 40 and 80 μM concentration (Figure 3.12 C, E and F).
Results
45
Figure 3.12: Effect of resveratrol and compound 5 (10 μM 24 h: A; 10 µM 48 h: B;
40 μM 24 h: C; 40 µM 48 h: D; 80 μM 24 h: E; 80 µM 48 h: F) on the cell cycle
distribution of HCA-7 cells. Results are presented as mean ± SD of four independent
experiments. +: p ≤ 0.001; *: p ≤ 0.0001.
Results
46
3.3. Effect of resveratrol and compound 5 on the COX-2/PGE2-pathway
3.3.1. Effect of resveratrol and compound 5 on COX-2 protein expression in
HCA-7 cells
In a next step, we investigated the potential regulation of COX-2 protein expression
and the PGE2 levels by resveratrol and compound 5. The COX-2 protein expression in
HCA-7 cells was evaluated by Western blotting, and cells were treated with
resveratrol and compound 5 at concentrations of 1, 50, and 100 µM for 24 h. As
shown in Figure 3.13, treatment with 100 µM resveratrol led to a reduced expression
of COX-2, whereas lower concentrations did not induce such an effect. In contrast,
compound 5 at concentrations of 50 and 100 µM increased the expression of this
protein when compared to DMSO-treated cells (Figure 3.13).
Figure 3.13: Effect of resveratrol and compound 5 on the expression of COX-2 in
HCA-7 cells. Representative images of three independent experiments.
Results
47
3.3.2. Effect of resveratrol and compound 5 on PGE2 production in HCA-7 cells
The data of compound 5-related effects on PGE2-production were kindly provided by
Ina Willenberg, and the results of resveratrol as well as the analysis method have
previously been reported (WILLENBERG et al. 2015a). According to this publication,
PGE2 levels were significantly reduced by a resveratrol treatment (WILLENBERG et
al. 2015a). Treatment with compound 5 (Figure 3.14) also led to a decrease in PGE2
production (Figure 3.14). The maximum inhibition (64 %) thereby occurred at a
concentration of 50 µM. The corresponding IC50 values of resveratrol and compound
5 are shown in Table 3.3. Resveratrol inhibited PGE2 production with an IC50 value of
4.7 µM, while compound 5 showed a stronger inhibitory activity, the IC50 value being
0.42 µM.
Figure 3.14: The effect of compound 5 on PGE2 production in HCA-7 cells. Cells were
treated with compound 5 (0, 1, 10 and 50 µM) for 24 h. Results are shown as the
mean of two independent exprements.
Results
48
Table 3.3. IC50 values of resveratrol and compound 5 on PGE2 production in HCA-7
cells [data for resveratrol taken from (WILLENBERG et al. 2015a)]
IC50 (μM)
resveratrol compound 5
HCA-7 4.7 0.42
3.4. Metabolic stability of compound 5
The data on the metabolic stability of compound 5 were kindly provided by Michael
Krohn, and the results for resveratrol as well as details regarding the methods used
have previously been reported (WILLENBERG et al. 2012). Compound 5 was
incubated with rat liver microsomes (RLMs) for 40 min, and as shown in Figure 3.15,
34 % of the unconjugated compound 5 was recovered after that time. Therefore, 66 %
of compound 5 was glucuronidated, while resveratrol was almost fully conjugated
[≈99 %; see (WILLENBERG et al. 2012)].
Figure 3.15: Glucuronidation of compound 5 by RLMs. Shown is the percentage of
free compound 5 after 40 min of incubation with RLMs, expressed as the
mean ± standard deviation of three samples.
Discussion
49
4. Discussion
The results can be summarized as follows: 1) Of the five IRA’s tested, only compound
5 had a significant growth-inhibitory effect on HCT-116p53wt cells, which in addition was
stronger than that of resveratrol; 2) Resveratrol and compound 5 suppressed the
growth of five other human tumor cell lines, the effects being however cell
line-dependent; 3) Resveratrol and compound 5 altered the cell cycle distribution in
different human tumor cell lines, again depending on the concentration and the cell
type; 4) The expression of COX-2 was down-regulated by resveratrol, while it was
up-regulated by compound 5, and resveratrol as well as compound 5 inhibited PGE2
production; 5) Compound 5 is less metabolized to glucuronic acid conjugates in RLMs
when compared to resveratrol.
4.1. Effect of resveratrol and IRAs on the proliferation of human tumor cell
lines
Firstly, an investigation of the anti-proliferative activity of resveratrol and five IRAs on
HCT-116p53wt cells were performed, the results showing that only compound 5 had a
far stronger activity than that of resveratrol in these cells. The growth inhibitory effect
of resveratrol on HCT-116p53wt cells reported in the present work is consistent with
previous studies (LU et al. 2012; FOUAD et al. 2013). Resveratrol has a pronounced
growth-inhibitory effect on these cells, but compound 5 exerts even stronger effects
than those of resveratrol, as shown by its approximately 30 times lower IC50 value.
The fact that IC50 value calculation shows that compound 5 has a stronger
growth-inhibitory effect on HCT-116p53wt cells indicates that p53 most probably
mediates growth inhibition in these colon carcinoma cells. p53 is a tumor suppressor
and plays an important role in cell cycle distribution (MAXIMOV et al. 2008). Activation
of p53 can lead to cell cycling arrest in the G1, S and G2 phases, thereby preventing
cell proliferation (LODISH et al. 2008). Therefore, the stronger inhibitory effect of
compound 5 on HCT-116p53wt cells is probably related to the activation of p53.
Discussion
50
LU et al. (2012) suggested, based on the fact that compound 5 is a much more potent
antioxidant agent than resveratrol, that simple chemical alterations of resveratrol at
the B ring with an ortho-OH group might retain or enhance its biological activity.
However, the investigation of the effects of compound 5 on all the other tumor cell
lines in our study supports the view that substitution modification at the aromatic rings
of resveratrol does not notably modify its antiproliferative effects. The IC50 values
thereby indicate that A-431 cells are the most sensitive cell line regarding a treatment
with resveratrol, while compound 5 is the most effective substance in HCT-116 cells.
In the present study, resveratrol exhibited a stronger inhibitory effect in Caco-2 cells
than in the HCT-116 cell line, and this is consistent with a previous study (LIU et al.
2014). Moreover, Caco-2 cells exposed to compound 5 are also more sensitive to
resveratrol than HCT-116 cells expressing or not expressing the p53 gene. The
analysis of the effects of compound 5 showed a comparable antiproliferative effect on
LNCaP cells, which suggests that the growth-inhibitory effects of resveratrol
analogues were similar to those of resveratrol in this prostate cancer cell line, while
resveratrol is more potent than compound 5 in HCA-7 cells. All in all, the effect of
compound 5 is only stronger in HCT-116p53wt cells, which might be due to the
p53-mediated cell cycle arrest or to the activation of cell repair mechanisms.
4.2. Effect of resveratrol and compound 5 on cell cycle distribution
Growth inhibition is closely associated with cell cycle disturbance and apoptosis in
tumor cells (COTTART et al. 2014). Resveratrol has been reported to affect cell
growth via the induction of a cell cycle arrest, even though not consistently in different
cell lines (AGGARWAL et al. 2004; COTTART et al. 2014). WOLTER et al. (2001)
reported that treatment with resveratrol in the 12.5-200 µM dose range after 24 h
resulted in HCT-116 cells accumulating in the G2 or S phase. In the present study,
after 24 h of incubation, resveratrol led to a slight HCT-116p53wt cell number increase
in the G2 phase at 10 µM and to a significant cell cycle arrest in the S phase at 40 µM,
which is consistent with the previously cited study (WOLTER et al. 2001). Compound
Discussion
51
5 also caused a cell cycle arrest, but different from that induced by resveratrol. Cells
were arrested in the G2 phase (40 µM) and the S phase (80 µM) after 24 h of
incubation. The fact that the growth inhibition exerted by compound 5 is more
pronounced in HCT-116p53wt than in HCT-116p53-/- cells is probably due to effects
mediated by p53. p53 is a transcription factor that induces the expression of p21CIP,
which can inhibit the activity of the Cyclin A/CDK2 complex and thus could induce an
S phase arrest (WAWRYK-GAWDA et al. 2014). Moreover, the S phase arrest could
be due to compound 5 inducing DNA damage at 80 µM. No apoptosis in HCT-116p53wt
cells was observed in our study; thus, the indicated cell growth inhibitory may not be
related to apoptotic events. Resveratrol is known to increase the expression of
proapoptotic proteins in a concentration-dependent manner. The maximal
concentration used in the present study was 80 µM, which might be too low when
wanting to induce apoptosis, as shown in previous studies (MAHYAR-ROEMER et al.
2001; LIU et al. 2014).
In HCT-116p53-/- cells, the effect of resveratrol on the cell cycle at high but not at low
concentrations is the same as in the case of HCT-116p53wt cells. MAHYAR-ROEMER
et al. (2001) reported that resveratrol induced apoptosis in HCT-116 cells
independently of p53, but apoptosis was not detected in our study, since no enhanced
accumulation of cells in the Sub-G1 phase was observed. In the present study, the fact
that the same cell cycle arrest was observed in HCT-116p53wt and HCT-116p53-/- cells
after being treated with a high concentration of resveratrol suggests that the
resveratrol-induced cell cycle arrest is not associated with p53. In contrast, the results
obtained with compound 5 support the view that p53 is involved in the cell cycle arrest
observed in HCT-116p53wt cells.
In the present study, the effect of resveratrol and compound 5 on the cell cycle
distribution of A-431 cells was analyzed and shown not to match with results of
previously published studies. AHMAD et al. (2001) reported that a resveratrol
treatment led to a cell cycle arrest in the G1 phase after an incubation of 24 h in the
Discussion
52
1-50 µM dose range, whereas resveratrol induced an accumulation of cells in the G1
phase (10 µM) and G2 phase (40 µM) in the present study. The accumulation at
10 µM might be explained in the same way as previously described (AHMAD et al.
2001), i.e. resveratrol induced WAF/p21 expression, thus inhibiting the formation of
cyclin D-CDK4/6 and cyclin E-CDK2 complexes and resulting in a G1 phase arrest of
the cells. A resveratrol concentration of 40 µM led to a cell cycle arrest in the G2 phase,
which provides time for cells to undergo apoptosis (DIPAOLA 2002; KAJSTURA et al.
2007). This was actually confirmed after incubating the cells with 80 µM resveratrol,
which resulted in a significant increase of cells in the Sub-G1 phase. Compound 5 was
found to have the same effect as resveratrol at high concentrations, but induced a cell
cycle arrest in the S phase at 40 µM, which was accompanied by a significant
decrease of cells in the G1 phase. Therefore, the growth-inhibitory effect of compound
5 on A-431 cells is most probably due to a disturbance of the cell cycle, i.e. the
induction of a cell cycle arrest in the S phase.
The effect of resveratrol on LNCaP cells has been controversially discussed in the
scientific literature. HSIEH et al. (1999) reported that 2.5 µM resveratrol failed to
cause any effect on the cell cycle after 4 days of incubation. KUWAJERWALA et al.
(2002) reported that treatment with 10 and 20 µM resveratrol led to an accumulation
of LNCaP cells in the S phase after 24 h incubation. BENITEZ et al. (2007) showed
that 50 µM resveratrol induced an increase of the cell counts in the S phase, but only
at higher concentrations (100 and 150 µM) did resveratrol lead to an increasing
number of cells in the G1 phase. The present study showed that resveratrol led a
significant G1 phase arrest after incubation with 10-80 µM for 24 h, which is in line with
recent studies (WANG et al. 2010; EMPL et al. 2015). Again, the inconsistent results
indicated by the above-mentioned studies may be due to different incubation times
and cell batches used. As in the case of resveratrol, cells exposed to compound 5
(10-80 µM) accumulated in the G1 phase. Therefore, the compound 5-induced growth
inhibition is most probably due to the induction of a cell cycle arrest in the G1 phase.
Discussion
53
In Caco-2 cells, we found out that concentrations lower than 40 µM resveratrol caused
a significant cellular accumulation in the S phase, which is in agreement with a
previously published study (WOLTER et al. 2001). Since at higher concentrations
(80 µM) resveratrol induced an accumulation of cells in the Sub-G1 phase, this is most
probably due to the induction of apoptotic processes (KAJSTURA et al. 2007). The
resveratrol induced G1/S phase arrest is mediated by a reduction in the formation of
the cyclin D1-CDK4 complex (MUSGROVE et al. 1994). The compound 5-mediated
arrest in the G1 and S phase at 80 µM might be due to the same effect.
In the present study, resveratrol induced an arrest of HCA-7 cells in the G1 (24 h) and
S phase (48h), which is consistent with a previously published study (SALE et al.
2005). Compound 5 mainly caused a cell accumulation in the G1 phase at
concentrations of 40 and 80 µM. One explanation for this effect may be the reduction
of cyclin D, CDK4 and 6 by compound 5, thereby causing a G1 phase arrest
(MUSGROVE et al. 1994). Another explanation could be that compound 5 leads to the
activation of the peroxisome proliferator-activated receptor gamma (PPAR-γ), which is
associated with G1 phase arrest in human colorectal tumor cell lines (BROCKMAN et
al. 1998; KRISHNAN et al. 2007). SMITH et al. (2000) reported that NSAIDs may
inhibit the proliferation of HCA-7 cells and lead to a cell cycle arrest by activation of
PPAR-γ.
All in all, the effect of compound 5 on the cell cycle is similar to that of resveratrol in
the tested human cancer cell lines, since both compounds interfered with cell cycle
distribution. Nevertheless, the data regarding resveratrol shown herein is not in
complete agreement with previously published studies. This might partly be due to
different cell culture media, protocol use, time points or test substance concentrations
used. Depending on the cell type, these effects of compound 5 might be mediated
through cyclins and CDK’s, cyclin-dependent kinase inhibitors or nuclear receptors.
However, the mechanism underlying the observed cell cycle arrest(s) would need
further investigation.
Discussion
54
4.3. Effect of resveratrol and compound 5 on the COX-2/PGE2-pathway
COX-2 and PGE2 have been described as tumor promoters in cancer progression
(GREENHOUGH et al. 2009). Studies have demonstrated that COX-2 and PGE2
might support tumor progression by increasing tumor growth and invasiveness
(WANG et al. 2005; SOBOLEWSKI et al. 2010). Coxibs and other NSAIDs were found
to exert a positive cancer chemopreventive effect (FISCHER et al. 2011). The
mechanism by which most NSAIDs reduce cancer progression involves the
COX-2/PGE2 pathway (CHA et al. 2007; FISCHER et al. 2011). Therefore, it was
important to evaluate the effect of compound 5 on the COX-2/PGE2 pathway. In our
study, HCA-7 cells were used as a model for investigating this matter, since they
overexpress COX-2 (SHENG et al. 1997).
Our results show that resveratrol can inhibit COX-2 protein expression in HCA-7 cells,
which is consistent with a previous study (SALE et al. 2005). COX-2 expression was
only slightly inhibited by resveratrol after a 24 h-incubation. In contrast, compound 5
dramatically enhanced COX-2 expression at a concentration of 50 and 100 µM. The
levels of PGE2 were also analyzed in the present study, compound 5 thereby
exhibiting a stronger effect on the PGE2 levels. Resveratrol is known to be a COX
inhibitor. SUBBARAMAIAH et al. (1998) showed that resveratrol inhibited COX-2
transcription and activity in phorbol ester-treated human mammary epithelial cells.
The mechanism underlying the up-regulation of COX-2 expression is not clear. The
transcription factor NF-kB may be involved in the control of the transcription of this
gene, and NF-kB activation by compound 5 probably contributes to the increase in
COX-2 expression (LI et al. 2011). PGE2 also positively regulates the expression of
COX-2 (BENOIT et al. 2004; VICHAI et al. 2005) .Therefore, it is possible that the
treatment with compound 5 inhibited PGE2 production, and the decreased PGE2
levels might have led to a compensatory up-regulation of the transcription of the
COX-2 gene to increase the amount of COX-2 protein.
4.4. Metabolism of compound 5
Discussion
55
Resveratrol has been shown to inhibit the growth of a broad panel of tumor cells in
vitro (COTTART et al. 2014; GAMBINI et al. 2015). However, studies have
demonstrated that the bioavailability of resveratrol in rats and humans is low
(ANDLAUER et al. 2000; WALLE et al. 2004). Resveratrol is readily absorbed, but is
then rapidly metabolized (GOLDBERG et al. 2003; WALLE et al. 2004). The
concentration of unconjugated resveratrol in vivo is too low to induce the same effects
as those observed in vitro (BOOCOCK et al. 2007a; BOOCOCK et al. 2007b).
However, the bioavailability of resveratrol could be enhanced by the accumulation of
resveratrol and its metabollites in different tissues after absorption of the mother
compound (WALLE 2011). Therefore, it made sense to evaluate the metabolism of
compound 5.
Recent studies have demonstrated that the metabolic stability of resveratrol and
related polyphenols can be determined by an in vitro glucuronidation assay (SCHEBB
et al. 2012; WILLENBERG et al. 2012). Therefore, in our study, we investigated the
metabolic stability of compound 5 by using the same assay and compared it with that
of resveratrol. Compound 5 was shown to be conjugated by RLMs after 40 min
incubation. About 66% of compound 5 was found to be conjugated, a conjugation rate
that is about one third lower than that of resveratrol (99%). The comparison suggests
that the stability of compound 5 is higher than that of resveratrol, but compound 5 is
still metabolized to a great extent. Moreover, the absorption rate of compound 5 is not
known, this may represent a limitation when wanting assess its effects in vivo. The
metabolic stability of compound 5 in humans also needs to be further investigated.
Discussion
56
References
57
5. References
ABRAMSON, S. B. u. G. WEISSMANN (1989):
The mechanisms of action of nonsteroidal antiinflammatory drugs.
Arthritis and rheumatism 32, 1-9
AGGARWAL, B. B., et al. (2004):
Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies.
Anticancer research 24, 2783-2840
AHMAD, N., et al. (2001):
Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human
epidermoid carcinoma A431 cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 7, 1466-1473
ANAND, P., et al. (2008):
Cancer is a preventable disease that requires major lifestyle changes.
Pharmaceutical research 25, 2097-2116
ANDLAUER, W., et al. (2000):
Assessment of resveratrol bioavailability in the perfused small intestine of the rat.
Drugs under experimental and clinical research 26, 47-55
ARELLANO, M. u. S. MORENO (1997):
Regulation of CDK/cyclin complexes during the cell cycle.
The international journal of biochemistry & cell biology 29, 559-573
ARTS, I. C., et al. (2001):
Dietary catechins and epithelial cancer incidence: the Zutphen elderly study.
International journal of cancer. Journal international du cancer 92, 298-302
ARTS, I. C. W., et al. (2002):
Dietary catechins and cancer incidence among postmenopausal women: the Iowa Women's Health Study
(United States).
Cancer Cause Control 13, 373-382
ATTEN, M. J., et al. (2001):
Resveratrol-induced inactivation of human gastric adenocarcinoma cells through a protein kinase C-mediated
mechanism.
Biochemical pharmacology 62, 1423-1432
BAKHLE, Y. S. u. R. M. BOTTING (1996):
Cyclooxygenase-2 and its regulation in inflammation.
References
58
Mediators of inflammation 5, 305-323
BANERJEE, S., et al. (2002):
Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of
nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9.
Cancer research 62, 4945-4954
BENITEZ, D. A., et al. (2007):
Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines.
Journal of andrology 28, 282-293
BENOIT, V., et al. (2004):
Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2.
Oncogene 23, 1631-1635
BHAT, K. P., et al. (2001a):
Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models.
Cancer research 61, 7456-7463
BHAT, K. P. L., et al. (2001b):
Biological effects of resveratrol.
Antioxidants & redox signaling 3, 1041-1064
BOFFETTA, P., et al. (2010):
Fruit and Vegetable Intake and Overall Cancer Risk in the European Prospective Investigation Into Cancer and
Nutrition (EPIC).
Journal of the National Cancer Institute 102, 529-537
BOOCOCK, D. J., et al. (2007a):
Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer
chemopreventive agent.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research,
cosponsored by the American Society of Preventive Oncology 16, 1246-1252
BOOCOCK, D. J., et al. (2007b):
Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high
performance liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 848, 182-187
BROCKMAN, J. A., et al. (1998):
Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer
cells.
Gastroenterology 115, 1049-1055
References
59
BRZOZOWSKI, T., et al. (2005):
Role of prostaglandins in gastroprotection and gastric adaptation.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 56 Suppl 5, 33-55
BUJANDA, L., et al. (2006):
Effect of resveratrol on alcohol-induced mortality and liver lesions in mice.
BMC gastroenterology 6, 35
BUNTING, S., et al. (1976):
Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of
mesenteric and coeliac ateries and inhibits platelet aggregation.
Prostaglandins 12, 897-913
CAO, Y. u. S. M. PRESCOTT (2002):
Many actions of cyclooxygenase-2 in cellular dynamics and in cancer.
Journal of cellular physiology 190, 279-286
CELOTTI, E., et al. (1996):
Resveratrol content of some wines obtained from dried Valpolicella grapes: Recioto and Amarone.
Journal of chromatography. A 730, 47-52
CHA, Y. I. u. R. N. DUBOIS (2007):
NSAIDs and cancer prevention: targets downstream of COX-2.
Annual review of medicine 58, 239-252
CHAMPERIS TSANIRAS, S., et al. (2014):
Licensing of DNA replication, cancer, pluripotency and differentiation: an interlinked world?
Seminars in cell & developmental biology 30, 174-180
CHAN, M. W., et al. (2007):
Targeted inhibition of COX-2 expression by RNA interference suppresses tumor growth and potentiates
chemosensitivity to cisplatin in human gastric cancer cells.
Oncology reports 18, 1557-1562
CLEMENT, M. V., et al. (1998):
Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent
apoptosis in human tumor cells.
Blood 92, 996-1002
COTTART, C. H., et al. (2014):
Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans.
Molecular nutrition & food research 58, 7-21
COUSSENS, L. M. u. Z. WERB (2002):
References
60
Inflammation and cancer.
Nature 420, 860-867
CUI, J., et al. (2010):
Antiproliferative effect of resveratrol in pancreatic cancer cells.
Phytotherapy research : PTR 24, 1637-1644
D'ARCHIVIO, M., et al. (2010):
Bioavailability of the polyphenols: status and controversies.
International journal of molecular sciences 11, 1321-1342
DAI, Z. J., et al. (2012):
Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in Vitro and in Vivo.
Cancer cell international 12, 53
DAVIES, N. J., et al. (2011):
The role of diet and physical activity in breast, colorectal, and prostate cancer survivorship: a review of the
literature.
British journal of cancer 105 Suppl 1, S52-73
DELMAS, D., et al. (2003):
Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a
death-inducing signaling complex in colon cancer cells.
The Journal of biological chemistry 278, 41482-41490
DEWITT, D. L., et al. (1993):
PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs.
The American journal of medicine 95, 40S-44S
DEWITT, D. L. u. W. L. SMITH (1988):
Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the
complementary DNA sequence.
Proceedings of the National Academy of Sciences of the United States of America 85, 1412-1416
DEY, I., et al. (2006):
Prostaglandin E2 receptor distribution and function in the gastrointestinal tract.
British journal of pharmacology 149, 611-623
DI POPOLO, A., et al. (2000):
IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon
carcinoma cells.
Oncogene 19, 5517-5524
DIPAOLA, R. S. (2002):
References
61
To arrest or not to G(2)-M Cell-cycle arrest : commentary re: A. K. Tyagi et al., Silibinin strongly synergizes
human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G(2)-M arrest, and apoptosis.
Clin. cancer res., 8: 3512-3519, 2002.
Clinical cancer research : an official journal of the American Association for Cancer Research 8, 3311-3314
DIVISI, D., et al. (2006):
Diet and cancer.
Acta bio-medica : Atenei Parmensis 77, 118-123
EASTON, J., et al. (1998):
Disruption of the cyclin D/cyclin-dependent kinase/INK4/retinoblastoma protein regulatory pathway in human
neuroblastoma.
Cancer research 58, 2624-2632
EBERHART, C. E., et al. (1994):
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas.
Gastroenterology 107, 1183-1188
ELLEDGE, S. J. (1996):
Cell cycle checkpoints: preventing an identity crisis.
Science 274, 1664-1672
EMPL, M. T., et al. (2015):
The Resveratrol Tetramer r-Viniferin Induces a Cell Cycle Arrest Followed by Apoptosis in the Prostate Cancer
Cell Line LNCaP.
Phytotherapy research : PTR 29, 1640-1645
EVANS, T., et al. (1983):
Cyclin: a protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division.
Cell 33, 389-396
FERLAY, J., et al. (2015):
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
International journal of cancer. Journal international du cancer 136, E359-386
FERRIERES, J. (2004):
The French paradox: lessons for other countries.
Heart 90, 107-111
FISCHER, S. M., et al. (2011):
Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention.
Cancer Prev Res (Phila) 4, 1728-1735
FITZMAURICE, C., et al. (2015):
References
62
The Global Burden of Cancer 2013.
JAMA oncology 1, 505-527
FOUAD, M. A., et al. (2013):
Resveratrol inhibits proliferation, angiogenesis and induces apoptosis in colon cancer cells: calorie restriction is
the force to the cytotoxicity.
Human & experimental toxicology 32, 1067-1080
FUNK, C. D. u. G. A. FITZGERALD (2007):
COX-2 inhibitors and cardiovascular risk.
Journal of cardiovascular pharmacology 50, 470-479
GALDERISI, U., et al. (2003):
Cell cycle regulation and neural differentiation.
Oncogene 22, 5208-5219
GAMBINI, J., et al. (2015):
Properties of Resveratrol: In Vitro and In Vivo Studies about Metabolism, Bioavailability, and Biological Effects in
Animal Models and Humans.
Oxidative medicine and cellular longevity 2015, 837042
GOBEC, M., et al. (2015):
Antioxidant and anti-inflammatory properties of 1,2,4-oxadiazole analogs of resveratrol.
Chemico-biological interactions 240, 200-207
GOLDBERG, D. M., et al. (2003):
Absorption of three wine-related polyphenols in three different matrices by healthy subjects.
Clinical biochemistry 36, 79-87
GREENHOUGH, A., et al. (2009):
The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour
microenvironment.
Carcinogenesis 30, 377-386
HARTWELL, L. H. u. T. A. WEINERT (1989):
Checkpoints: controls that ensure the order of cell cycle events.
Science 246, 629-634
HSIEH, T. C. u. J. M. WU (1999):
Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate
cancer cell lines.
Experimental cell research 249, 109-115
HSU, A. L., et al. (2000):
References
63
The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer
cells independently of Bcl-2.
The Journal of biological chemistry 275, 11397-11403
HUSSAIN, S. P. u. C. C. HARRIS (2007):
Inflammation and cancer: An ancient link with novel potentials.
International Journal of Cancer 121, 2373-2380
JACKSON, L. M., et al. (2000):
Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa.
Gut 47, 762-770
JACOBY, R. F., et al. (2000):
The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model
of adenomatous polyposis.
Cancer research 60, 5040-5044
JANG, M., et al. (1997):
Cancer Chemopreventive Activity of Resveratrol, a Natural Product Derived from Grapes.
Science 275, 218-220
JANG, M. u. J. M. PEZZUTO (1998):
Effects of resveratrol on 12-O-tetradecanoylphorbol-13-acetate-induced oxidative events and gene expression
in mouse skin.
Cancer letters 134, 81-89
JOE, A. K., et al. (2002):
Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several
human cancer cell lines.
Clinical cancer research : an official journal of the American Association for Cancer Research 8, 893-903
KAGEURA, T., et al. (2001):
Inhibitors from rhubarb on lipopolysaccharide-induced nitric oxide production in macrophages: structural
requirements of stilbenes for the activity.
Bioorganic & medicinal chemistry 9, 1887-1893
KAJSTURA, M., et al. (2007):
Discontinuous fragmentation of nuclear DNA during apoptosis revealed by discrete "sub-G1" peaks on DNA
content histograms.
Cytometry. Part A : the journal of the International Society for Analytical Cytology 71, 125-131
KANAOKA, S., et al. (2007):
Cyclooxygenase-2 and tumor biology.
Advances in clinical chemistry 43, 59-78
References
64
KARGMAN, S., et al. (1996):
Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts.
Gastroenterology 111, 445-454
KAWAMORI, T., et al. (2003):
Enhancement of colon carcinogenesis by prostaglandin E2 administration.
Carcinogenesis 24, 985-990
KELLER, J. J. u. F. M. GIARDIELLO (2003):
Chemoprevention strategies using NSAIDs and COX-2 inhibitors.
Cancer biology & therapy 2, S140-S149
KIM, A. L., et al. (2006):
Resveratrol inhibits proliferation of human epidermoid carcinoma A431 cells by modulating MEK1 and AP-1
signalling pathways.
Experimental dermatology 15, 538-546
KOTORA, P., et al. (2016):
The Scavenging of DPPH, Galvinoxyl and ABTS Radicals by Imine Analogs of Resveratrol.
Molecules 21, 127
KRISHNAN, A., et al. (2007):
Biology of PPAR gamma in cancer: a critical review on existing lacunae.
Current molecular medicine 7, 532-540
KUHNLE, G., et al. (2000):
Resveratrol is absorbed in the small intestine as resveratrol glucuronide.
Biochemical and biophysical research communications 272, 212-217
KUWAJERWALA, N., et al. (2002):
Resveratrol induces prostate cancer cell entry into S phase and inhibits DNA synthesis.
Cancer Res 62, 2488-2492
LEES, E. (1995):
Cyclin dependent kinase regulation.
Current opinion in cell biology 7, 773-780
LI, S. Y., et al. (2014):
Design, synthesis and biological evaluation of imine resveratrol derivatives as multi-targeted agents against
Alzheimer's disease.
Eur J Med Chem 71, 36-45
LI, Y. S., et al. (2011):
References
65
Involvement of nuclear factor kappaB (NF-kappaB) in the downregulation of cyclooxygenase-2 (COX-2) by
genistein in gastric cancer cells.
The Journal of international medical research 39, 2141-2150
LI, Z. G., et al. (2002):
Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by
resveratrol.
Carcinogenesis 23, 1531-1536
LIN, H. Y., et al. (2008):
Resveratrol causes COX-2- and p53-dependent apoptosis in head and neck squamous cell cancer cells.
Journal of cellular biochemistry 104, 2131-2142
LIU, B., et al. (2014):
Resveratrol inhibits proliferation in human colorectal carcinoma cells by inducing G1/Sphase cell cycle arrest
and apoptosis through caspase/cyclinCDK pathways.
Molecular medicine reports 10, 1697-1702
LIU, Z., et al. (2012):
Effects of resveratrol on vascular endothelial growth factor expression in osteosarcoma cells and cell
proliferation.
Oncology letters 4, 837-839
LODISH, H., et al. (2008):
Molecular Cell Biology W. H. Freeman, New York
LU, J., et al. (2012):
The antioxidant effect of imine resveratrol analogues.
Bioorganic & medicinal chemistry letters 22, 5744-5747
MAHYAR-ROEMER, M., et al. (2001):
Resveratrol induces colon tumor cell apoptosis independently of p53 and precede by epithelial differentiation,
mitochondrial proliferation and membrane potential collapse.
International journal of cancer. Journal international du cancer 94, 615-622
MALFERTHEINER, P., et al. (2009):
Peptic ulcer disease.
Lancet 374, 1449-1461
MANACH, C., et al. (2004):
Polyphenols: food sources and bioavailability.
The American journal of clinical nutrition 79, 727-747
MAREL, A. K., et al. (2008):
Inhibitory effects of trans-resveratrol analogs molecules on the proliferation and the cell cycle progression of
References
66
human colon tumoral cells.
Molecular nutrition & food research 52, 538-548
MATSUOKA, A., et al. (2001):
Resveratrol, a naturally occurring polyphenol, induces sister chromatid exchanges in a Chinese hamster lung
(CHL) cell line.
Mutation research 494, 107-113
MAXIMOV, G. K. u. K. G. MAXIMOV (2008):
The role of p53 tumor-suppressor protein in apoptosis and cancerogenesis.
MIENE, C., et al. (2011):
Impact of polyphenol metabolites produced by colonic microbiota on expression of COX-2 and GSTT2 in human
colon cells (LT97).
Nutrition and cancer 63, 653-662
MURAKAMI, M. u. I. KUDO (2004):
Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway.
Progress in lipid research 43, 3-35
MURIAS, M., et al. (2004):
Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship.
Bioorganic & medicinal chemistry 12, 5571-5578
MUSGROVE, E. A., et al. (1994):
Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the
cell cycle.
Proceedings of the National Academy of Sciences of the United States of America 91, 8022-8026
NAKANISHI, M. u. D. W. ROSENBERG (2013):
Multifaceted roles of PGE2 in inflammation and cancer.
Seminars in immunopathology 35, 123-137
NARAYANAN, B. A., et al. (2003):
Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets.
International journal of cancer. Journal international du cancer 104, 204-212
ONOE, Y., et al. (1996):
IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in
osteoblasts.
J Immunol 156, 758-764
PACEASCIAK, C. R., et al. (1996):
Wines and grape juices as modulators of platelet aggregation in healthy human subjects.
References
67
Clin Chim Acta 246, 163-182
PARK, J. Y., et al. (2006):
Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases.
Clin Immunol 119, 229-240
PENG, G., et al. (2006):
Green tea polyphenol (-)-epigallocatechin-3-gallate inhibits cyclooxygenase-2 expression in colon
carcinogenesis.
Molecular carcinogenesis 45, 309-319
PINES, J. (1991):
Cyclins - Wheels within Wheels.
Cell Growth & Differentiation 2, 305-310
POLIGONE, B. u. A. S. BALDWIN (2001):
Positive and negative regulation of NF-kappaB by COX-2: roles of different prostaglandins.
The Journal of biological chemistry 276, 38658-38664
POULSEN, M. M., et al. (2013):
Resveratrol in metabolic health: an overview of the current evidence and perspectives.
Annals of the New York Academy of Sciences 1290, 74-82
POUSSIER, B., et al. (2005):
Resveratrol inhibits vascular smooth muscle cell proliferation and induces apoptosis.
Journal of vascular surgery 42, 1190-1197
POZO-GUISADO, E., et al. (2002):
The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast
cancer cells: cell-specific alteration of the cell cycle.
Biochemical pharmacology 64, 1375-1386
RAEDERSTORFF, D., et al. (2013):
Resveratrol, from experimental data to nutritional evidence: the emergence of a new food ingredient.
Annals of the New York Academy of Sciences 1290, 136-141
RISTIMAKI, A., et al. (1997):
Expression of cyclooxygenase-2 in human gastric carcinoma.
Cancer research 57, 1276-1280
RONGHE, A., et al. (2014):
Differential regulation of estrogen receptors alpha and beta by
4-(E)-{(4-hydroxyphenylimino)-methylbenzene,1,2-diol}, a novel resveratrol analog.
J Steroid Biochem 144, 500-512
References
68
ROTCHES-RIBALTA, M., et al. (2012):
Pharmacokinetics of resveratrol metabolic profile in healthy humans after moderate consumption of red wine
and grape extract tablets.
Pharmacological research : the official journal of the Italian Pharmacological Society 66, 375-382
RUMZHUM, N. N. u. A. J. AMMIT (2015):
Cyclooxygenase 2: its regulation, role and impact in airway inflammation.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
SALE, S., et al. (2005):
Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans
3,4,5,4'-tetramethoxystilbene (DMU-212) on adenoma development in the Apc(Min+) mouse and
cyclooxygenase-2 in human-derived colon cancer cells.
International journal of cancer. Journal international du cancer 115, 194-201
SALE, S., et al. (2004):
Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent
resveratrol and the synthetic analogue trans 3,4,5,4'-tetramethoxystilbene.
British journal of cancer 90, 736-744
SATYANARAYANA, A. u. P. KALDIS (2009):
Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms.
Oncogene 28, 2925-2939
SCALBERT, A., et al. (2005):
Dietary polyphenols and the prevention of diseases.
Critical reviews in food science and nutrition 45, 287-306
SCALBERT, A. u. G. WILLIAMSON (2000):
Dietary intake and bioavailability of polyphenols.
The Journal of nutrition 130, 2073S-2085S
SCHEBB, N. H., et al. (2012):
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
Drug metabolism and disposition: the biological fate of chemicals 40, 25-31
SCHNEIDER, Y., et al. (2000):
Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells.
Cancer letters 158, 85-91
SECCHIERO, P., et al. (2005):
Potential pathogenetic implications of cyclooxygenase-2 overexpression in B chronic lymphoid leukemia cells.
The American journal of pathology 167, 1599-1607
References
69
SEIBERT, K., et al. (1997):
Distribution of COX-1 and COX-2 in normal and inflamed tissues.
Advances in experimental medicine and biology 400A, 167-170
SERRERO, G. u. R. LU (2001):
Effect of resveratrol on the expression of autocrine growth modulators in human breast cancer cells.
Antioxidants & redox signaling 3, 969-979
SERSEN, F., et al. (2009):
Antioxidative effect of some hydroxy substituted aromatic bisimines.
Gen Physiol Biophys 28, 210-214
SHAW, P. H. (1996):
The Role of p53 in Cell Cycle Regulation.
Pathology - Research and Practice 192, 669-675
SHE, Q. B., et al. (2002):
Involvement of c-jun NH(2)-terminal kinases in resveratrol-induced activation of p53 and apoptosis.
Molecular carcinogenesis 33, 244-250
SHENG, H., et al. (1997):
Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2.
The Journal of clinical investigation 99, 2254-2259
SHENG, H., et al. (2001):
Prostaglandin E2 increases growth and motility of colorectal carcinoma cells.
The Journal of biological chemistry 276, 18075-18081
SKEHAN, P., et al. (1990):
New colorimetric cytotoxicity assay for anticancer-drug screening.
Journal of the National Cancer Institute 82, 1107-1112
SMITH, M. L., et al. (2000):
The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different
mechanisms of action.
Eur J Cancer 36, 664-674
SOBOLEWSKI, C., et al. (2010):
The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies.
International journal of cell biology 2010, 215158
STEINMETZ, K. A. u. J. D. POTTER (1996):
Vegetables, fruit, and cancer prevention: a review.
Journal of the American Dietetic Association 96, 1027-1039
References
70
STIVALA, L. A., et al. (2001):
Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of
resveratrol.
The Journal of biological chemistry 276, 22586-22594
STROBER, W. (2001):
Trypan blue exclusion test of cell viability.
Current protocols in immunology / edited by John E. Coligan ... [et al.] Appendix 3, Appendix 3B
SUBBARAMAIAH, K., et al. (1998):
Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary
epithelial cells.
The Journal of biological chemistry 273, 21875-21882
SUGANUMA, M., et al. (1999):
Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient
mice.
Cancer research 59, 4516-4518
TESSITORE, L., et al. (2000):
Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression.
Carcinogenesis 21, 1619-1622
TOME-CARNEIRO, J., et al. (2013):
Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence.
Current pharmaceutical design 19, 6064-6093
TRAVERSA, G., et al. (1995):
Gastroduodenal toxicity of different nonsteroidal antiinflammatory drugs.
Epidemiology 6, 49-54
VANE, J. R. (1971):
Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs.
Nature: New biology 231, 232-235
VANE, J. R., et al. (1998):
Cyclooxygenases 1 and 2.
Annual review of pharmacology and toxicology 38, 97-120
VENKATACHALAM, S., et al. (1998):
Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote
cancer formation.
The EMBO journal 17, 4657-4667
References
71
VERMEULEN, K., et al. (2003):
The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer.
Cell proliferation 36, 131-149
VICHAI, V. u. K. KIRTIKARA (2006):
Sulforhodamine B colorimetric assay for cytotoxicity screening.
Nature protocols 1, 1112-1116
VICHAI, V., et al. (2005):
Positive feedback regulation of COX-2 expression by prostaglandin metabolites.
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 54, 163-172
WALLE, T. (2011):
Bioavailability of resveratrol.
Annals of the New York Academy of Sciences 1215, 9-15
WALLE, T., et al. (2004):
High absorption but very low bioavailability of oral resveratrol in humans.
Drug Metabolism and Disposition 32, 1377-1382
WANG, D., et al. (2005):
Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein
kinase cascade.
Cancer research 65, 1822-1829
WANG, D. u. R. N. DUBOIS (2006):
Prostaglandins and cancer.
Gut 55, 115-122
WANG, T. T., et al. (2010):
Differential effects of resveratrol and its naturally occurring methylether analogs on cell cycle and apoptosis in
human androgen-responsive LNCaP cancer cells.
Molecular nutrition & food research 54, 335-344
WAWRYK-GAWDA, E., et al. (2014):
P53 protein in proliferation, repair and apoptosis of cells.
Protoplasma 251, 525-533
WILLENBERG, I., et al. (2012):
Development of a rapid LC-UV method for the investigation of chemical and metabolic stability of resveratrol
oligomers.
Journal of agricultural and food chemistry 60, 7844-7850
References
72
WILLENBERG, I., et al. (2015a):
Food Polyphenols Fail to Cause a Biologically Relevant Reduction of COX-2 Activity.
PloS one 10, e0139147
WILLENBERG, I., et al. (2015b):
Targeted metabolomics of the arachidonic acid cascade: current state and challenges of LC-MS analysis of
oxylipins.
Analytical and bioanalytical chemistry 407, 2675-2683
WILSON, J. W. u. C. S. POTTEN (2000):
The effect of exogenous prostaglandin administration on tumor size and yield in Min/+ mice.
Cancer research 60, 4645-4653
WOLTER, F., et al. (2001):
Downregulation of the cyclin D1/Cdk4 complex occurs during resveratrol-induced cell cycle arrest in colon
cancer cell lines.
The Journal of nutrition 131, 2197-2203
YOKOYAMA, C., et al. (1988):
Primary structure of sheep prostaglandin endoperoxide synthase deduced from cDNA sequence.
FEBS letters 231, 347-351
YUSOF, A. S., et al. (2012):
Dietary Patterns and Risk of Colorectal Cancer: A Systematic Review of Cohort Studies (2000-2011).
Asian Pacific Journal of Cancer Prevention 13, 4713-4717
ZENG, Y. W., et al. (2013):
Strategies of functional food for cancer prevention in human beings.
Asian Pacific journal of cancer prevention : APJCP 14, 1585-1592
ZHOU, J. H., et al. (2011):
Resveratrol induces apoptosis in pancreatic cancer cells.
Chinese medical journal 124, 1695-1699
Annex
73
6. Annex
Solutions in materials
1 % acetic acid solution solution
20 ml acetic acid acetic acid
500 ml ddH2O
0.4% SRB solution
2 g Sulforhodamine B
500 ml 1 % acetic acid solution
50 % TCA solution
2.5 g TCA
500 ml ddH2O
Tris buffer (pH 10.5)
1.2114 g Tris
1000 ml ddH2O
PBS (pH 7.4)
0.4 g KCl
0.2 g KH2PO4
8 g NaCl
1.43 g Na2HPO4 • 2H2O
1000 ml ddH2O
RNase A solution
1 mg RNase
1 ml ddH2O
Protein lysis buffer (pH 6.8)
12 g Urea
Annex
74
0.25g SDS
0.4 g Tris
50 ml ddH2O
Separating gel buffer (pH 8.8)
56.5 g Tris
2 g SDS
200 ml ddH2O
Stacking gel buffer (pH 6.8)
56.5 g Tris
1 g SDS
200 ml ddH2O
5 X protein loading buffer
2.4024 g Urea
1 g SDS
0.0756 g Tris
0.02% Bromophenol blue
10 ml ddH2O, before using add 20 % DTT
2 X protein loading buffer
0.2 g SDS
0.0756 g Tris
0.02% Bromophenol blue
10 ml ddH2O
10 X Running buffer (pH 8.3)
30.3 g Tris
10 g SDS
144 g Glycin
1000 ml ddH2O
Annex
75
1 X Running buffer
100 ml 10 X Running buffer
900 ml ddH2O
10 X Transfer buffer (pH 8.2-8.4)
30.39 g Tris
144 g Glycin
840 ml ddH2O
1 X Transfer buffer (pH 8.3)
84 ml 10 X Transfer buffer
756 ml ddH2O
160 ml Methanol
1 M Tris solution (pH 7.5)
24.2 g Tris
200 ml ddH2O
5 M NaCl solution
146.1 g NaCl
500 ml ddH2O
1 X Washing buffer
10 ml 1 M Tris solution
30 ml 5 M NaCl solution
0.5 ml Tween® 20
1000 ml ddH2O
Blocking buffer
5 mg milk powder
10 ml 1 X Washing buffer
10% Acrylamide separating gel
Annex
76
7 ml ddH2O
4.99 ml 30 % Acrylamide/Bis-Acrylamid (37.5:1)
3 ml Separating gel buffer
112.5 μl 10 % Ammonium Persulfate (APS)
12 μl Tetramethylethylenediamine (TEMED)
Stacking gel
6.33 ml ddH2O
1.65 ml 30 % Acrylamide/Bis-Acrylamid (37.5:1)
2 ml Separating gel buffer
75 μl 10 % Ammonium Persulfate (APS)
8 μl Tetramethylethylenediamine (TEMED)
Acknowledgments
77
7. Acknowledgments
Firstly, I would like to thank my supervisor Prof. Dr. Pablo Steinberg for providing the
opportunity to work in his great team. Prof. Dr. Pablo Steinberg has always been nice
and patient to help and answer all my questions. I am very lucky to be guided by him.
Secondly, I want to express my deepest gratitude to Dr. Michael Empl for his open and
patient attitude and for giving me numberless valuable comments. He is a very
warm-hearted person, and he helped me a lot in my laboratory work and in my life. I
would not have succeeded in my PhD project without his guidance and support.
I also would like to thank the members of my supervisor group, Prof. Dr. Hassan Y.
Naim and Prof. Dr. Peter Winterhalter. Thanks a lot for their enthusiastic comments
and assistance in all my presentations and meetings.
Thanks a lot to Prof. Dr. Y. Pan for kindly providing the substances used in my PhD
program. Also many thanks to Dr. Ina Willenberg and Michael Krohn for their kind
contribution during my PhD project.
I would like to thank the Department of Immunobiology and Department of
Microbiology for their assistance and permission to work with their laboratory
equipment.
Many thanks to my colleagues Ulrike Oberjatzas, Dr. Maria Brauneis, Dr. Petra Nicken,
Dr. Stephanie Vogel, Janine Döhring, Bettina Seeger, Nicole Brauer and Julia
Hausmann for always helping me with my work. It has really been nice to spend a
wonderful part of my lab life together with them.
I want to give my countless thanks to my friends Dr. Laura Bartel and Dr. Ping-Ping
Tsai for their encouragement and caring during the past years. They encouraged me
to be more self-confident in my work and took care of me a lot at the beginning of my
life in Hannover.
Acknowledgments
78
Also thanks a lot to my Chinese friends Ning Zhang, Lin Li and Wei Wang for their nice
help and advices in my daily life. It is a very precious memory for the time we spent
together abroad.
Special thanks to my family, my mother and my brothers. Thanks a lot for your support
and for giving me the freedom to realize my dream.
Finally, I want to thanks China Scholarship Council (CSC) for financial support during
my study in Germany.